<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:georss="http://www.georss.org/georss" xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" xmlns:media="http://search.yahoo.com/mrss/"
	>

<channel>
	<title>New Drug Approvals</title>
	<atom:link href="https://newdrugapprovals.org/feed/" rel="self" type="application/rss+xml" />
	<link>https://newdrugapprovals.org</link>
	<description>PROUD Indian WORLD RECORD VIEWS holder on THIS BLOG, .........live, by DR ANTHONY MELVIN CRASTO, Worldpeaceambassador, Worlddrugtracker,  Helping millions, 100 million hits on google, pushing boundaries,2.5 lakh plus connections worldwide, 45 lakh plus VIEWS on this blog  in 227 countries, 7 CONTINENTS ......A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair, [THIS BLOG HOLDS WORLD RECORD VIEWS ] A PROUD INDIAN</description>
	<lastBuildDate>Thu, 19 Nov 2026 03:08:07 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>http://wordpress.com/</generator>
<site xmlns="com-wordpress:feed-additions:1">46419963</site><cloud domain='newdrugapprovals.org' port='80' path='/?rsscloud=notify' registerProcedure='' protocol='http-post' />
<source:cloud xmlns:source='https://source.scripting.com/'>https://newdrugapprovals.org/?rsscloud=notify</source:cloud>
<image>
		<url>https://s2.wp.com/i/webclip.png</url>
		<title>New Drug Approvals</title>
		<link>https://newdrugapprovals.org</link>
	</image>
	<atom:link rel="search" type="application/opensearchdescription+xml" href="https://newdrugapprovals.org/osd.xml" title="New Drug Approvals" />
	<atom:link rel='hub' href='https://newdrugapprovals.org/?pushpress=hub'/>
	<item>
		<title>Giredestrant</title>
		<link>https://newdrugapprovals.org/2026/11/19/giredestrant/</link>
					<comments>https://newdrugapprovals.org/2026/11/19/giredestrant/#respond</comments>
		
		<dc:creator><![CDATA[DR ANTHONY MELVIN CRASTO Ph.D]]></dc:creator>
		<pubDate>Thu, 19 Nov 2026 03:07:54 +0000</pubDate>
				<category><![CDATA[APPROVALS 2026]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[FDA 2026]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[28P3DU6DB3]]></category>
		<category><![CDATA[anax labs]]></category>
		<category><![CDATA[breast cancer]]></category>
		<category><![CDATA[GDC 9545]]></category>
		<category><![CDATA[Giredestrant]]></category>
		<category><![CDATA[RG 6171]]></category>
		<category><![CDATA[RG6171]]></category>
		<category><![CDATA[RO 7197597]]></category>
		<category><![CDATA[RO7197597]]></category>
		<category><![CDATA[Wilserdly]]></category>
		<guid isPermaLink="false">http://newdrugapprovals.org/?p=34433</guid>

					<description><![CDATA[Giredestrant CAS 1953133-47-5 MF C27H31F5N4O MW 522.6 g/mol 3-[(1R,3R)-1-[2,6-difluoro-4-[[1-(3-fluoropropyl)azetidin-3-yl]amino]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2,2-difluoropropan-1-ol 3-((1R,3R)-1-(2,6-Difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol (1R,3R)-1-[2,6-Difluoro-4-[[1-(3-fluoropropyl)-3-azetidinyl]amino]phenyl]-beta,beta-difluoro-1,3,4,9-tetrahydro-3-methyl-2H-pyrido[3,4-b]indole-2-propanol Wilserdly, FDA 2026, APPROVALS 2026, GDC 9545, RG 6171, RO 7197597, 28P3DU6DB3 To treat adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor 1-mutated locally advanced or metastatic breast cancer whose disease has recurred during or after endocrine-based adjuvant therapy, or &#8230; <a href="https://newdrugapprovals.org/2026/11/19/giredestrant/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
										<content:encoded><![CDATA[
<figure class="wp-block-image size-large is-resized"><a href="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-10.jpg"><img width="1024" height="529" data-attachment-id="34436" data-permalink="https://newdrugapprovals.org/2026/11/19/giredestrant/str1-586/" data-orig-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-10.jpg" data-orig-size="1647,852" data-comments-opened="1" data-image-title="STR1" data-image-description="" data-image-caption="" data-large-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-10.jpg?w=500" src="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-10.jpg?w=1024" alt="" class="wp-image-34436" style="aspect-ratio:1.935762638628835;width:435px;height:auto" srcset="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-10.jpg?w=1024 1024w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-10.jpg?w=150 150w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-10.jpg?w=300 300w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-10.jpg?w=768 768w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-10.jpg?w=1440 1440w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-10.jpg 1647w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph">Giredestrant</p>



<p class="wp-block-paragraph">CAS 1953133-47-5</p>



<p class="wp-block-paragraph">MF C<sub>27</sub>H<sub>31</sub>F<sub>5</sub>N<sub>4</sub>O MW 522.6 g/mol</p>



<p class="wp-block-paragraph">3-[(1<em>R</em>,3<em>R</em>)-1-[2,6-difluoro-4-[[1-(3-fluoropropyl)azetidin-3-yl]amino]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2,2-difluoropropan-1-ol</p>



<ul class="wp-block-list">
<li><a href="https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%223-((1R%2C3R)-1-(2%2C6-Difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1%2C3%2C4%2C9-tetrahydro-2H-pyrido%5B3%2C4-b%5Dindol-2-yl)-2%2C2-difluoropropan-1-ol%22[CompleteSynonym]%20AND%20121410806[StandardizedCID]" target="_blank" rel="noopener">3-((1R,3R)-1-(2,6-Difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol</a></li>



<li><a href="https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22(1R%2C3R)-1-%5B2%2C6-Difluoro-4-%5B%5B1-(3-fluoropropyl)-3-azetidinyl%5Damino%5Dphenyl%5D-beta%2Cbeta-difluoro-1%2C3%2C4%2C9-tetrahydro-3-methyl-2H-pyrido%5B3%2C4-b%5Dindole-2-propanol%22[CompleteSynonym]%20AND%20121410806[StandardizedCID]" target="_blank" rel="noopener">(1R,3R)-1-[2,6-Difluoro-4-[[1-(3-fluoropropyl)-3-azetidinyl]amino]phenyl]-beta,beta-difluoro-1,3,4,9-tetrahydro-3-methyl-2H-pyrido[3,4-b]indole-2-propanol</a></li>
</ul>



<p class="wp-block-paragraph">Wilserdly, FDA 2026, APPROVALS 2026, GDC 9545, RG 6171, RO 7197597, <a href="https://gsrs.ncats.nih.gov/ginas/app/beta/substances/28P3DU6DB3">28P3DU6DB3</a></p>



<p class="wp-block-paragraph">To treat adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor 1-mutated locally advanced or metastatic breast cancer whose disease has recurred during or after endocrine-based adjuvant therapy, or has progressed on at least one endocrine-based regimen in the metastatic setting</p>



<p class="wp-block-paragraph">Giredestrant is an orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, giredestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.</p>



<p class="wp-block-paragraph" id="mwCA"><strong>Giredestrant</strong>, sold under the brand name <strong>Wilserdly</strong>, is an oral <a href="https://en.wikipedia.org/wiki/Selective_estrogen_receptor_degrader">selective estrogen receptor degrader</a> (SERD) used for the treatment of <a href="https://en.wikipedia.org/wiki/Estrogen_receptor">estrogen receptor</a>-positive (ER+) <a href="https://en.wikipedia.org/wiki/Breast_cancer">breast cancer</a>.<sup><a href="https://en.wikipedia.org/wiki/Giredestrant#cite_note-nciformulary-1">[1]</a></sup><sup><a href="https://en.wikipedia.org/wiki/Giredestrant#cite_note-Malhi_2023-2">[2]</a></sup> It is a potent, nonsteroidal compound that antagonizes estrogen effects by competitively binding to both wild-type and mutant estrogen receptors with nanomolar potency.<sup><a href="https://en.wikipedia.org/wiki/Giredestrant#cite_note-nciformulary-1">[1]</a></sup><sup><a href="https://en.wikipedia.org/wiki/Giredestrant#cite_note-Roche-3">[3]</a></sup> Giredestrant works by inducing an inactive conformation of the estrogen receptor ligand-binding domain and promoting <a href="https://en.wikipedia.org/wiki/Proteasome">proteasome</a>-mediated degradation of the receptor protein.<sup><a href="https://en.wikipedia.org/wiki/Giredestrant#cite_note-nciformulary-1">[1]</a></sup><sup><a href="https://en.wikipedia.org/wiki/Giredestrant#cite_note-Jhaveri_2024-4">[4]</a></sup><sup><a href="https://en.wikipedia.org/wiki/Giredestrant#cite_note-Liang_2021-5">[5]</a></sup></p>



<h2 id="Research" class="wp-block-heading">Research</h2>



<p class="wp-block-paragraph" id="mwLA">In clinical trials, giredestrant has been evaluated in patients with ER+breast cancer , including those with ESR1 mutations, both as a single agent and in combination with other therapies.<sup><a href="https://en.wikipedia.org/wiki/Giredestrant#cite_note-Malhi_2023-2">[2]</a></sup><sup><a href="https://en.wikipedia.org/wiki/Giredestrant#cite_note-Lawrence_2024-6">[6]</a></sup> Its orally <a href="https://en.wikipedia.org/wiki/Bioavailable">bioavailable</a>.<sup><a href="https://en.wikipedia.org/wiki/Giredestrant#cite_note-Roche-3">[3]</a></sup><sup><a href="https://en.wikipedia.org/wiki/Giredestrant#cite_note-Jhaveri_2024-4">[4]</a></sup></p>



<p class="wp-block-paragraph">SCHEME</p>



<figure class="wp-block-image size-large is-resized"><a href="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-6.jpg"><img width="584" height="1023" data-attachment-id="34463" data-permalink="https://newdrugapprovals.org/2026/11/19/giredestrant/str2-89/" data-orig-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-6.jpg" data-orig-size="794,1392" data-comments-opened="1" data-image-title="STR2" data-image-description="" data-image-caption="" data-large-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-6.jpg?w=500" src="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-6.jpg?w=584" alt="" class="wp-image-34463" style="width:531px;height:auto" srcset="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-6.jpg?w=584 584w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-6.jpg?w=86 86w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-6.jpg?w=171 171w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-6.jpg?w=768 768w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-6.jpg 794w" sizes="(max-width: 584px) 100vw, 584px" /></a></figure>



<p class="wp-block-paragraph">PAT</p>



<p class="wp-block-paragraph">WO2016097072 &#8211; TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF</p>



<p class="wp-block-paragraph">F HOFFMANN LA ROCHE &#8211; WO2016/97072, 2016, A1, <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016097072&amp;_cid=P22-MWMY5D-43733-1">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016097072&amp;_cid=P22-MWMY5D-43733-1</a></p>



<p class="wp-block-paragraph">PAT</p>



<p class="wp-block-paragraph">US20160175289 &#8211; Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof</p>



<p class="wp-block-paragraph"><a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=US174233194&amp;_cid=P22-MWMXSA-28614-1">https://patentscope.wipo.int/search/en/detail.jsf?docId=US174233194&amp;_cid=P22-MWMXSA-28614-1</a></p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph">SYN</p>



<p class="wp-block-paragraph"><a href="https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22compound%2035%20%5BPMID%3A%2034251202%5D%22[CompleteSynonym]%20AND%20121410806[StandardizedCID]" target="_blank" rel="noopener">compound 35 [PMID: 34251202]</a></p>



<p class="wp-block-paragraph"><strong>Journal of Medicinal Chemistry</strong>, <strong>2021</strong>, vol. 64, # 16, p. 11841 &#8211; 11856</p>



<figure class="wp-block-image size-large is-resized"><a href="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-6.jpg"><img width="787" height="512" data-attachment-id="34461" data-permalink="https://newdrugapprovals.org/2026/11/19/giredestrant/s1-105/" data-orig-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-6.jpg" data-orig-size="787,512" data-comments-opened="1" data-image-title="S1" data-image-description="" data-image-caption="" data-large-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-6.jpg?w=500" src="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-6.jpg?w=787" alt="" class="wp-image-34461" style="width:459px;height:auto" srcset="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-6.jpg 787w, https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-6.jpg?w=150 150w, https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-6.jpg?w=300 300w, https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-6.jpg?w=768 768w" sizes="(max-width: 787px) 100vw, 787px" /></a></figure>



<p class="wp-block-paragraph">SYN</p>



<p class="wp-block-paragraph"><a href="https://www.sciencedirect.com/org/science/article/abs/pii/S1083616022002432">https://www.sciencedirect.com/org/science/article/abs/pii/S1083616022002432</a></p>



<h2 class="wp-block-heading"><a href="https://www.sciencedirect.com/org/journal/organic-process-research-and-development">Organic Process Research &amp; Development</a>, <strong>Date:</strong> 18 March 2022, <strong>Pages:</strong> 568-582 <strong>Volume:</strong> <a href="https://www.sciencedirect.com/org/journal/organic-process-research-and-development/vol/26/issue/3">Volume 26, Issue 3</a></h2>



<p class="wp-block-paragraph">GDC-9545 is a selective estrogen receptor degrader that is being developed as a treatment for ER+/HER2– breast cancer. A robust, convergent manufacturing process for GDC-9545 was developed. The process features a Wenker aziridine synthesis to produce the key starting material tryptamine <strong>11</strong>, a highly efficient C–N coupling between aminoazetidine <strong>9</strong> and 2,6-difluoro-4-bromobenzaldehyde diethyl acetal (<strong>33</strong>) to construct key intermediate <strong>10</strong>, and a crystallization-driven diastereoselective Pictet–Spengler reaction to furnish the active pharmaceutical ingredient GDC-9545·tartrate.</p>



<figure class="wp-block-image size-large"><a href="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-5.jpg"><img loading="lazy" width="851" height="257" data-attachment-id="34454" data-permalink="https://newdrugapprovals.org/2026/11/19/giredestrant/s1-104/" data-orig-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-5.jpg" data-orig-size="851,257" data-comments-opened="1" data-image-title="S1" data-image-description="" data-image-caption="" data-large-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-5.jpg?w=500" src="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-5.jpg?w=851" alt="" class="wp-image-34454" srcset="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-5.jpg 851w, https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-5.jpg?w=150 150w, https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-5.jpg?w=300 300w, https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-5.jpg?w=768 768w" sizes="auto, (max-width: 851px) 100vw, 851px" /></a></figure>



<p class="wp-block-paragraph">PATENTS</p>



<ul class="wp-block-list">
<li><a href="https://pubchem.ncbi.nlm.nih.gov/patent/US-12233052-B2">Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof</a>Publication Number:<a href="https://pubchem.ncbi.nlm.nih.gov/patent/US-12233052-B2">US-12233052-B2</a>Priority Date:2014-12-18Grant Date:2025-02-25</li>



<li><a href="https://pubchem.ncbi.nlm.nih.gov/patent/EP-3760623-A1">Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof</a>Publication Number:<a href="https://pubchem.ncbi.nlm.nih.gov/patent/EP-3760623-A1">EP-3760623-A1</a>Priority Date:2014-12-18</li>



<li><a href="https://pubchem.ncbi.nlm.nih.gov/patent/TW-I784255-B">TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF</a>Publication Number:<a href="https://pubchem.ncbi.nlm.nih.gov/patent/TW-I784255-B">TW-I784255-B</a>Priority Date:2014-12-18Grant Date:2022-11-21</li>



<li><a href="https://pubchem.ncbi.nlm.nih.gov/patent/US-9980947-B2">Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof</a>Publication Number:<a href="https://pubchem.ncbi.nlm.nih.gov/patent/US-9980947-B2">US-9980947-B2</a>Priority Date:2014-12-18Grant Date:2018-05-29</li>
</ul>



<ul class="wp-block-list">
<li><a href="https://pubchem.ncbi.nlm.nih.gov/patent/TW-I699363-B">TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF</a>Publication Number:<a href="https://pubchem.ncbi.nlm.nih.gov/patent/TW-I699363-B">TW-I699363-B</a>Priority Date:2014-12-18Grant Date:2020-07-21</li>



<li><a href="https://pubchem.ncbi.nlm.nih.gov/patent/EP-3233852-B1">Tetrahydro-pyrido[3,4-b]indoles as estrogen receptor modulators and uses thereof</a>Publication Number:<a href="https://pubchem.ncbi.nlm.nih.gov/patent/EP-3233852-B1">EP-3233852-B1</a>Priority Date:2014-12-18Grant Date:2020-07-15</li>



<li><a href="https://pubchem.ncbi.nlm.nih.gov/patent/US-2025114338-A1">TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF</a>Publication Number:<a href="https://pubchem.ncbi.nlm.nih.gov/patent/US-2025114338-A1">US-2025114338-A1</a>Priority Date:2014-12-18</li>



<li><a href="https://pubchem.ncbi.nlm.nih.gov/patent/JP-7446348-B2">Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof</a>Publication Number:<a href="https://pubchem.ncbi.nlm.nih.gov/patent/JP-7446348-B2">JP-7446348-B2</a>Priority Date:2014-12-18Grant Date:2024-03-08</li>



<li><a href="https://pubchem.ncbi.nlm.nih.gov/patent/US-2016175289-A1">TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF</a>Publication Number:<a href="https://pubchem.ncbi.nlm.nih.gov/patent/US-2016175289-A1">US-2016175289-A1</a>Priority Date:2014-12-18</li>
</ul>



<p class="wp-block-paragraph"><strong>ADVERTISEMENT</strong></p>



<p class="wp-block-paragraph"><strong>ANAX LABORATORIES</strong></p>



<p class="wp-block-paragraph">WEBSITE <a href="https://www.anaxlab.com/">https://www.anaxlab.com/</a></p>



<p class="wp-block-paragraph"><a href="https://www.anaxlab.com/"><strong>Discovery Solutions</strong></a>, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences</p>



<p class="wp-block-paragraph"><a href="https://www.anaxlab.com/">Development Solutions</a>, Developing from Lab scale to PR&amp;D, Kilo Scale-ups and Commercial Scales</p>



<p class="wp-block-paragraph">SEE MORE&#8230;&#8230;&#8230;<a href="https://www.anaxlab.com/">Integrated Solutions</a>, <a href="https://www.anaxlab.com/">Manufacturing Solutions</a>, <a href="https://www.anaxlab.com/products">Products</a>,<br><a href="https://www.anaxlab.com/contact">Can&#8217;t Find? Let&#8217;s Connect</a></p>



<figure class="wp-block-image size-large"><a href="https://newdrugapprovals.org/wp-content/uploads/2026/05/image-81.png"><img loading="lazy" width="618" height="103" data-attachment-id="31235" data-permalink="https://newdrugapprovals.org/2026/05/12/elsovaptan/image-659/" data-orig-file="https://newdrugapprovals.org/wp-content/uploads/2026/05/image-81.png" data-orig-size="618,103" data-comments-opened="1" data-image-title="image" data-image-description="" data-image-caption="" data-large-file="https://newdrugapprovals.org/wp-content/uploads/2026/05/image-81.png?w=500" src="https://newdrugapprovals.org/wp-content/uploads/2026/05/image-81.png?w=618" alt="" class="wp-image-31235" srcset="https://newdrugapprovals.org/wp-content/uploads/2026/05/image-81.png 618w, https://newdrugapprovals.org/wp-content/uploads/2026/05/image-81.png?w=150 150w, https://newdrugapprovals.org/wp-content/uploads/2026/05/image-81.png?w=300 300w" sizes="auto, (max-width: 618px) 100vw, 618px" /></a></figure>



<p class="wp-block-paragraph"><a href="https://newdrugapprovals.org/wp-content/uploads/2026/01/image.png"></a><strong>Phone :&nbsp;</strong>+91&nbsp;897704 2010 / &nbsp;+91 9177075735, <strong>Email :&nbsp;</strong><a href="mailto:info@anaxlab.com">info@anaxlab.com</a></p>



<p class="wp-block-paragraph"><a href="https://www.linkedin.com/search/results/all/?keywords=%23medicinalchemistry&amp;origin=HASH_TAG_FROM_FEED">#MedicinalChemistry</a>, <a href="https://www.linkedin.com/search/results/all/?keywords=%23drugdiscovery&amp;origin=HASH_TAG_FROM_FEED">#DrugDiscovery</a>, <a href="https://www.linkedin.com/search/results/all/?keywords=%23organicsynthesis&amp;origin=HASH_TAG_FROM_FEED">#OrganicSynthesis</a>, <a href="https://www.linkedin.com/search/results/all/?keywords=%23chemicallibrary&amp;origin=HASH_TAG_FROM_FEED&amp;lipi=urn%3Ali%3Apage%3Ad_flagship3_detail_base%3B7Nok72e6SI6pSENnVtf7gQ%3D%3D">#ChemicalLibrary</a>, <a href="https://www.linkedin.com/search/results/all/?keywords=%23buildingblocks&amp;origin=HASH_TAG_FROM_FEED">#BuildingBlocks</a>, <a href="https://www.linkedin.com/search/results/all/?keywords=%23sarstudies&amp;origin=HASH_TAG_FROM_FEED">#SARStudies</a>, <a href="https://www.linkedin.com/search/results/all/?keywords=%23chemistryinnovation&amp;origin=HASH_TAG_FROM_FEED">#ChemistryInnovation</a>, <a href="https://www.linkedin.com/search/results/all/?keywords=%23medchem&amp;origin=HASH_TAG_FROM_FEED">#medchem</a>, <a href="https://www.linkedin.com/search/results/all/?keywords=%23drugdevelopment&amp;origin=HASH_TAG_FROM_FEED">#Drugdevelopment</a>, <a href="https://www.linkedin.com/search/results/all/?keywords=%23biotech&amp;origin=HASH_TAG_FROM_FEED">#Biotech</a>, <a href="https://www.linkedin.com/search/results/all/?keywords=%23biotechnology&amp;origin=HASH_TAG_FROM_FEED">#Biotechnology</a>, <a href="https://www.linkedin.com/search/results/all/?keywords=%23anaxlaboratories&amp;origin=HASH_TAG_FROM_FEED">#AnaxLaboratories</a>, <a href="https://www.linkedin.com/search/results/all/?keywords=%23pharma&amp;origin=HASH_TAG_FROM_FEED">#Pharma</a></p>



<figure class="wp-block-image is-resized"><a href="https://newdrugapprovals.org/wp-content/uploads/2023/01/cons-open-a-m-crasto.jpg"><img loading="lazy" width="1024" height="564" data-attachment-id="26263" data-permalink="https://newdrugapprovals.org/2023/01/22/myself-anthony-crasto-up-for-grabs-as-advisor-api-int-chem/cons-open-a-m-crasto/" data-orig-file="https://newdrugapprovals.org/wp-content/uploads/2023/01/cons-open-a-m-crasto.jpg" data-orig-size="1221,673" data-comments-opened="1" data-image-title="cons-open-a-m-crasto" data-image-description="" data-image-caption="" data-large-file="https://newdrugapprovals.org/wp-content/uploads/2023/01/cons-open-a-m-crasto.jpg?w=500" src="https://newdrugapprovals.org/wp-content/uploads/2023/01/cons-open-a-m-crasto.jpg?w=1024" alt="" class="wp-image-26263" style="aspect-ratio:1.8156641561687326;width:492px;height:auto" srcset="https://newdrugapprovals.org/wp-content/uploads/2023/01/cons-open-a-m-crasto.jpg?w=1024 1024w, https://newdrugapprovals.org/wp-content/uploads/2023/01/cons-open-a-m-crasto.jpg?w=150 150w, https://newdrugapprovals.org/wp-content/uploads/2023/01/cons-open-a-m-crasto.jpg?w=300 300w, https://newdrugapprovals.org/wp-content/uploads/2023/01/cons-open-a-m-crasto.jpg?w=768 768w, https://newdrugapprovals.org/wp-content/uploads/2023/01/cons-open-a-m-crasto.jpg 1221w" sizes="auto, (max-width: 1024px) 100vw, 1024px" /></a></figure>



<figure class="wp-block-image"><a href="http://drugapprovalsint.com/wp-content/uploads/2021/12/str1-17.jpg"><img src="https://i0.wp.com/drugapprovalsint.com/wp-content/uploads/2021/12/str1-17-300x160.jpg" alt="str1" class="wp-image-15152" /></a></figure>



<figure class="wp-block-image size-large is-resized"><a href="https://newdrugapprovals.org/wp-content/uploads/2026/02/image-138.png"><img loading="lazy" width="415" height="497" data-attachment-id="29565" data-permalink="https://newdrugapprovals.org/2026/02/25/olomorasib/image-217/" data-orig-file="https://newdrugapprovals.org/wp-content/uploads/2026/02/image-138.png" data-orig-size="415,497" data-comments-opened="1" data-image-title="image" data-image-description="" data-image-caption="" data-large-file="https://newdrugapprovals.org/wp-content/uploads/2026/02/image-138.png?w=415" src="https://newdrugapprovals.org/wp-content/uploads/2026/02/image-138.png?w=415" alt="" class="wp-image-29565" style="width:315px;height:auto" srcset="https://newdrugapprovals.org/wp-content/uploads/2026/02/image-138.png 415w, https://newdrugapprovals.org/wp-content/uploads/2026/02/image-138.png?w=125 125w, https://newdrugapprovals.org/wp-content/uploads/2026/02/image-138.png?w=251 251w" sizes="auto, (max-width: 415px) 100vw, 415px" /></a></figure>



<h3 class="wp-block-heading"><strong>AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT</strong></h3>



<figure class="wp-block-image is-resized" id="block-97f20ca3-89bf-4f06-8d2e-7bfa14bb5a13"><img src="https://newdrugapprovals.org/wp-content/uploads/2021/09/wdt-16.jpg" alt="wdt-16" style="aspect-ratio:1.9367389581381944;width:458px;height:auto" /></figure>



<p class="wp-block-paragraph">join me on Linkedin</p>



<h3 class="wp-block-heading"><a href="https://www.google.co.in/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=1&amp;cad=rja&amp;sqi=2&amp;ved=0CDAQFjAA&amp;url=http%3A%2F%2Fin.linkedin.com%2Fin%2Famcrasto&amp;ei=HC79UIPrOImQrgfThIHgCA&amp;usg=AFQjCNG33yHjtsBnClvr_2VJAspNSOCHjA&amp;sig2=S2Nt_xtNQcl_MGwq9T_I-Q&amp;bvm=bv.41248874,d.bmk"><em>Anthony Melvin Crasto</em>&nbsp;Ph.D – India |&nbsp;<em>LinkedIn</em></a></h3>



<p class="wp-block-paragraph">join me on Researchgate</p>



<h3 class="wp-block-heading"><a href="https://www.researchgate.net/profile/Anthony_Crasto">RESEARCHGATE</a></h3>



<figure class="wp-block-image" id="block-a1fe75ef-39d0-4b9f-a8db-f2ebbfd11320"><img src="https://newdrugapprovals.org/wp-content/uploads/2018/03/research.jpg?w=142" alt="This image has an empty alt attribute; its file name is research.jpg" /></figure>



<p class="wp-block-paragraph">join me on Facebook</p>



<h3 class="wp-block-heading"><em>Anthony Melvin Crasto</em>&nbsp;Dr. |&nbsp;<em>Facebook</em></h3>



<ul id="block-cc73c381-0233-4cde-8597-91f3069d5326" class="wp-block-list">
<li><a href="https://twitter.com/amcrasto">Twitter</a></li>



<li><a href="http://www.facebook.com/anthonymelvin.crasto">FACEBOOK</a></li>
</ul>



<p class="wp-block-paragraph">join me on twitter</p>



<p class="wp-block-paragraph"><em>Anthony Melvin Crasto</em>&nbsp;Dr. |&nbsp;<em>twitter</em></p>



<p class="wp-block-paragraph">+919321316780 call whatsaapp</p>



<p class="wp-block-paragraph">EMAIL. amcrasto@gmail.com</p>



<p class="wp-block-paragraph"></p>



<figure class="wp-block-image size-large is-resized"><a href="https://newdrugapprovals.org/wp-content/uploads/2025/07/image-2.png"><img loading="lazy" width="493" height="277" data-attachment-id="27244" data-permalink="https://newdrugapprovals.org/2025/07/16/keverprazan/image-40/" data-orig-file="https://newdrugapprovals.org/wp-content/uploads/2025/07/image-2.png" data-orig-size="493,277" data-comments-opened="1" data-image-title="image" data-image-description="" data-image-caption="" data-large-file="https://newdrugapprovals.org/wp-content/uploads/2025/07/image-2.png?w=493" src="https://newdrugapprovals.org/wp-content/uploads/2025/07/image-2.png?w=493" alt="" class="wp-image-27244" style="aspect-ratio:1.7798544343606792;width:467px;height:auto" srcset="https://newdrugapprovals.org/wp-content/uploads/2025/07/image-2.png 493w, https://newdrugapprovals.org/wp-content/uploads/2025/07/image-2.png?w=150 150w, https://newdrugapprovals.org/wp-content/uploads/2025/07/image-2.png?w=300 300w" sizes="auto, (max-width: 493px) 100vw, 493px" /></a></figure>



<h2 class="wp-block-heading"></h2>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td class="has-text-align-center" data-align="center" colspan="2"><a href="https://en.wikipedia.org/wiki/File:Giredestrant.svg"><img loading="lazy" src="https://thumb.wikimedia.org/wikipedia/commons/thumb/f/fc/Giredestrant.svg/250px-Giredestrant.svg.png?utm_source=en.wikipedia.org&amp;utm_campaign=parser&amp;utm_content=thumbnail" height="138" width="250"></a></td></tr><tr><th class="has-text-align-center" data-align="center" colspan="2">Clinical data</th></tr><tr><th class="has-text-align-left" data-align="left"><a href="https://en.wikipedia.org/wiki/Drug_nomenclature#Trade_names">Trade names</a></th><td class="has-text-align-left" data-align="left">Wilserdly</td></tr><tr><th class="has-text-align-left" data-align="left">Other names</th><td class="has-text-align-left" data-align="left">GDC-9545, RG6171, RO7197597</td></tr><tr><th class="has-text-align-center" data-align="center" colspan="2">Identifiers</th></tr><tr><td class="has-text-align-center" data-align="center" colspan="2"><a href="https://en.wikipedia.org/wiki/IUPAC_nomenclature_of_chemistry">IUPAC name</a></td></tr><tr><th class="has-text-align-left" data-align="left"><a href="https://en.wikipedia.org/wiki/CAS_Registry_Number">CAS Number</a></th><td class="has-text-align-left" data-align="left"><a href="https://commonchemistry.cas.org/detail?cas_rn=1953133-47-5">1953133-47-5</a></td></tr><tr><th class="has-text-align-left" data-align="left"><a href="https://en.wikipedia.org/wiki/PubChem#CID">PubChem</a> CID</th><td class="has-text-align-left" data-align="left"><a href="https://pubchem.ncbi.nlm.nih.gov/compound/121410806">121410806</a></td></tr><tr><th class="has-text-align-left" data-align="left"><a href="https://en.wikipedia.org/wiki/ChemSpider">ChemSpider</a></th><td class="has-text-align-left" data-align="left"><a href="https://www.chemspider.com/Chemical-Structure.103748880.html">103748880</a></td></tr><tr><th class="has-text-align-left" data-align="left"><a href="https://en.wikipedia.org/wiki/Unique_Ingredient_Identifier">UNII</a></th><td class="has-text-align-left" data-align="left"><a href="https://precision.fda.gov/uniisearch/srs/unii/28P3DU6DB3">28P3DU6DB3</a></td></tr><tr><th class="has-text-align-left" data-align="left"><a href="https://en.wikipedia.org/wiki/KEGG">KEGG</a></th><td class="has-text-align-left" data-align="left"><a href="https://www.kegg.jp/entry/D11961">D11961</a></td></tr><tr><th class="has-text-align-left" data-align="left"><a href="https://en.wikipedia.org/wiki/ChEMBL">ChEMBL</a></th><td class="has-text-align-left" data-align="left"><a href="https://www.ebi.ac.uk/chembl/explore/compound/ChEMBL4650316">ChEMBL4650316</a></td></tr><tr><th class="has-text-align-center" data-align="center" colspan="2">Chemical and physical data</th></tr><tr><th class="has-text-align-left" data-align="left"><a href="https://en.wikipedia.org/wiki/Chemical_formula">Formula</a></th><td class="has-text-align-left" data-align="left">C<sub>27</sub>H<sub>31</sub>F<sub>5</sub>N<sub>4</sub>O</td></tr><tr><th class="has-text-align-left" data-align="left"><a href="https://en.wikipedia.org/wiki/Molar_mass">Molar mass</a></th><td class="has-text-align-left" data-align="left">522.564&nbsp;g·mol<sup>−1</sup></td></tr><tr><th class="has-text-align-left" data-align="left">3D model (<a href="https://en.wikipedia.org/wiki/JSmol">JSmol</a>)</th><td class="has-text-align-left" data-align="left"><a href="https://chemapps.stolaf.edu/jmol/jmol.php?model=C%5BC%40%40H%5D1CC2%3DC%28%5BC%40H%5D%28N1CC%28CO%29%28F%29F%29C3%3DC%28C%3DC%28C%3DC3F%29NC4CN%28C4%29CCCF%29F%29NC5%3DCC%3DCC%3DC25">Interactive image</a></td></tr><tr><td class="has-text-align-center" data-align="center" colspan="2"><a href="https://en.wikipedia.org/wiki/Simplified_molecular-input_line-entry_system">SMILES</a></td></tr><tr><td class="has-text-align-center" data-align="center" colspan="2"><a href="https://en.wikipedia.org/wiki/International_Chemical_Identifier">InChI</a></td></tr></tbody></table></figure>



<h2 id="References" class="wp-block-heading">References</h2>



<ol id="mwQg" class="wp-block-list">
<li><a href="https://en.wikipedia.org/wiki/Giredestrant#cite_ref-nciformulary_1-0"></a><a href="https://en.wikipedia.org/wiki/Giredestrant#cite_ref-nciformulary_1-1"></a><a href="https://en.wikipedia.org/wiki/Giredestrant#cite_ref-nciformulary_1-2"></a> <a href="https://nciformulary.cancer.gov/available_agents/Giredestrant.htm">&#8220;Giredestrant (GDC-9545)&#8221;</a>. <em>Cancer.gov</em>. U.S. National Cancer Institute. 14 November 2024.</li>



<li><a href="https://en.wikipedia.org/wiki/Giredestrant#cite_ref-Malhi_2023_2-0"></a><a href="https://en.wikipedia.org/wiki/Giredestrant#cite_ref-Malhi_2023_2-1"></a> Malhi V, Agarwal P, Gates MR, Liu L, Wang J, De Bruyn T, et al. (December 2023). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10722959">&#8220;Optimizing Early-stage Clinical Pharmacology Evaluation to Accelerate Clinical Development of Giredestrant in Advanced Breast Cancer&#8221;</a>. <em>Cancer Research Communications</em>. <strong>3</strong> (12): 2551–2559. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)">doi</a>:<a href="https://doi.org/10.1158%2F2767-9764.CRC-23-0324">10.1158/2767-9764.CRC-23-0324</a>. <a href="https://en.wikipedia.org/wiki/PMC_(identifier)">PMC</a> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10722959">10722959</a>. <a href="https://en.wikipedia.org/wiki/PMID_(identifier)">PMID</a> <a href="https://pubmed.ncbi.nlm.nih.gov/38019116">38019116</a>.</li>



<li><a href="https://en.wikipedia.org/wiki/Giredestrant#cite_ref-Roche_3-0"></a><a href="https://en.wikipedia.org/wiki/Giredestrant#cite_ref-Roche_3-1"></a> <a href="https://forpatients.roche.com/en/trials/cancer/bc/a-study-to-evaluate-efficacy-and-safety-of-giredestrant-50902.html">&#8220;A clinical study to compare giredestrant with fulvestrant, both combined with a targeted therapy (CDK4/6 inhibitor) in people with ER-positive, HER2-negative breast cancer that has come back after adjuvant hormone therapy&#8221;</a>. <em>Roche</em>.</li>



<li><a href="https://en.wikipedia.org/wiki/Giredestrant#cite_ref-Jhaveri_2024_4-0"></a><a href="https://en.wikipedia.org/wiki/Giredestrant#cite_ref-Jhaveri_2024_4-1"></a> Jhaveri KL, Bellet M, Turner NC, Loi S, Bardia A, Boni V, et al. (February 2024). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10870118">&#8220;Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer&#8221;</a>. <em>Clinical Cancer Research</em>. <strong>30</strong> (4): 754–766. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)">doi</a>:<a href="https://doi.org/10.1158%2F1078-0432.CCR-23-1796">10.1158/1078-0432.CCR-23-1796</a>. <a href="https://en.wikipedia.org/wiki/PMC_(identifier)">PMC</a> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10870118">10870118</a>. <a href="https://en.wikipedia.org/wiki/PMID_(identifier)">PMID</a> <a href="https://pubmed.ncbi.nlm.nih.gov/37921755">37921755</a>.</li>



<li><a href="https://en.wikipedia.org/wiki/Giredestrant#cite_ref-Liang_2021_5-0"></a> Liang J, Zbieg JR, Blake RA, Chang JH, Daly S, DiPasquale AG, et al. (August 2021). &#8220;GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer&#8221;. <em>Journal of Medicinal Chemistry</em>. <strong>64</strong> (16): 11841–11856. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)">doi</a>:<a href="https://doi.org/10.1021%2Facs.jmedchem.1c00847">10.1021/acs.jmedchem.1c00847</a>. <a href="https://en.wikipedia.org/wiki/PMID_(identifier)">PMID</a> <a href="https://pubmed.ncbi.nlm.nih.gov/34251202">34251202</a>.</li>



<li><a href="https://en.wikipedia.org/wiki/Giredestrant#cite_ref-Lawrence_2024_6-0"></a> Lawrence L (25 July 2024). <a href="https://www.cancertherapyadvisor.com/news/giredestrant-anastrozole-er-her2-early-breast-cancer/">&#8220;Giredestrant Bests Anastrozole in ER+, HER2- Early Breast Cancer&#8221;</a>.</li>
</ol>



<h2 id="Further_reading" class="wp-block-heading">Further reading</h2>



<ul class="wp-block-list">
<li>Gheysen M, Punie K, Wildiers H, Neven P (November 2024). <a href="https://doi.org/10.1016%2Fj.ctrv.2024.102825">&#8220;Oral SERDs changing the scenery in hormone receptor positive breast cancer, a comprehensive review&#8221;</a>. <em>Cancer Treatment Reviews</em>. <strong>130</strong> 102825. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)">doi</a>:<a href="https://doi.org/10.1016%2Fj.ctrv.2024.102825">10.1016/j.ctrv.2024.102825</a>. <a href="https://en.wikipedia.org/wiki/PMID_(identifier)">PMID</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39293125">39293125</a>.</li>



<li>Guglielmi G, Del Re M, Gol LS, Bengala C, Danesi R, Fogli S (April 2024). <a href="https://doi.org/10.1016%2Fj.ejphar.2024.176424">&#8220;Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer&#8221;</a>. <em>European Journal of Pharmacology</em>. <strong>969</strong> 176424. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)">doi</a>:<a href="https://doi.org/10.1016%2Fj.ejphar.2024.176424">10.1016/j.ejphar.2024.176424</a>. <a href="https://en.wikipedia.org/wiki/Hdl_(identifier)">hdl</a>:<a href="https://hdl.handle.net/2434%2F1128718">2434/1128718</a>. <a href="https://en.wikipedia.org/wiki/PMID_(identifier)">PMID</a> <a href="https://pubmed.ncbi.nlm.nih.gov/38402929">38402929</a>.</li>



<li>Garcia-Fructuoso I, Gomez-Bravo R, Schettini F (November 2022). &#8220;Integrating new oral selective oestrogen receptor degraders in the breast cancer treatment&#8221;. <em>Current Opinion in Oncology</em>. <strong>34</strong> (6): 635–642. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)">doi</a>:<a href="https://doi.org/10.1097%2FCCO.0000000000000892">10.1097/CCO.0000000000000892</a>. <a href="https://en.wikipedia.org/wiki/PMID_(identifier)">PMID</a> <a href="https://pubmed.ncbi.nlm.nih.gov/36000362">36000362</a>.</li>



<li>Chen YC, Yu J, Metcalfe C, De Bruyn T, Gelzleichter T, Malhi V, et al. (June 2022). <a href="https://doi.org/10.1080%2F13543784.2021.1983542">&#8220;Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer&#8221;</a>. <em>Expert Opinion on Investigational Drugs</em>. <strong>31</strong> (6): 515–529. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)">doi</a>:<a href="https://doi.org/10.1080%2F13543784.2021.1983542">10.1080/13543784.2021.1983542</a>. <a href="https://en.wikipedia.org/wiki/PMID_(identifier)">PMID</a> <a href="https://pubmed.ncbi.nlm.nih.gov/34694932">34694932</a>.</li>



<li>Martín M, Lim E, Chavez-MacGregor M, Bardia A, Wu J, Zhang Q, et al. (June 2024). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11185917">&#8220;Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study&#8221;</a>. <em>Journal of Clinical Oncology</em>. <strong>42</strong> (18): 2149–2160. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)">doi</a>:<a href="https://doi.org/10.1200%2FJCO.23.01500">10.1200/JCO.23.01500</a>. <a href="https://en.wikipedia.org/wiki/PMC_(identifier)">PMC</a> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11185917">11185917</a>. <a href="https://en.wikipedia.org/wiki/PMID_(identifier)">PMID</a> <a href="https://pubmed.ncbi.nlm.nih.gov/38537155">38537155</a>.</li>
</ul>



<p class="wp-block-paragraph">/////////////Giredestrant, ANAX LABS, GDC 9545, RG 6171, RO 7197597, Wilserdly, FDA 2026, APPROVALS 2026, GDC-9545, RG6171, RO7197597, <a href="https://gsrs.ncats.nih.gov/ginas/app/beta/substances/28P3DU6DB3">28P3DU6DB3</a>, breast cancer </p>



<p class="wp-block-paragraph">#Giredestrant, #ANAX LABS, #GDC 9545, #RG 6171, #RO 7197597, #Wilserdly, #FDA 2026, #APPROVALS 2026, #GDC-9545, #RG6171, #RO7197597, #<a href="https://gsrs.ncats.nih.gov/ginas/app/beta/substances/28P3DU6DB3">28P3DU6DB3</a>, #breast cancer </p>



<p class="wp-block-paragraph"></p>
]]></content:encoded>
					
					<wfw:commentRss>https://newdrugapprovals.org/2026/11/19/giredestrant/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">34433</post-id>
		<media:content url="https://2.gravatar.com/avatar/569350c7858a75cbcaa674b4e28141525334a91c696621375b3bfee581907c13?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">amcrasto</media:title>
		</media:content>

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-10.jpg?w=1024" medium="image" />

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-6.jpg?w=584" medium="image" />

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-6.jpg?w=787" medium="image" />

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-5.jpg?w=851" medium="image" />

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2026/05/image-81.png?w=618" medium="image" />

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2023/01/cons-open-a-m-crasto.jpg?w=1024" medium="image" />

		<media:content url="https://i0.wp.com/drugapprovalsint.com/wp-content/uploads/2021/12/str1-17-300x160.jpg" medium="image">
			<media:title type="html">str1</media:title>
		</media:content>

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2026/02/image-138.png?w=415" medium="image" />

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2021/09/wdt-16.jpg" medium="image">
			<media:title type="html">wdt-16</media:title>
		</media:content>

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2018/03/research.jpg?w=142" medium="image">
			<media:title type="html">This image has an empty alt attribute; its file name is research.jpg</media:title>
		</media:content>

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2025/07/image-2.png?w=493" medium="image" />

		<media:content url="https://thumb.wikimedia.org/wikipedia/commons/thumb/f/fc/Giredestrant.svg/250px-Giredestrant.svg.png?utm_source=en.wikipedia.org&#038;utm_campaign=parser&#038;utm_content=thumbnail" medium="image" />
	</item>
		<item>
		<title></title>
		<link>https://newdrugapprovals.org/2026/11/18/34428/</link>
					<comments>https://newdrugapprovals.org/2026/11/18/34428/#respond</comments>
		
		<dc:creator><![CDATA[DR ANTHONY MELVIN CRASTO Ph.D]]></dc:creator>
		<pubDate>Wed, 18 Nov 2026 03:00:42 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<guid isPermaLink="false">http://newdrugapprovals.org/?p=34428</guid>

					<description><![CDATA[]]></description>
										<content:encoded><![CDATA[
<figure class="wp-block-embed is-type-wp-embed is-provider-new-drug-approvals wp-block-embed-new-drug-approvals"><div class="wp-block-embed__wrapper">
<blockquote class="wp-embedded-content" data-secret="xuoY209sko"><a href="https://newdrugapprovals.org/2025/12/15/vilzemetkib/">Vilzemetkib</a></blockquote><iframe loading="lazy" class="wp-embedded-content" sandbox="allow-scripts" security="restricted"  title="&#8220;Vilzemetkib&#8221; &#8212; New Drug Approvals" src="https://newdrugapprovals.org/2025/12/15/vilzemetkib/embed/#?secret=UW458AbzLQ#?secret=xuoY209sko" data-secret="xuoY209sko" width="500" height="282" frameborder="0" marginwidth="0" marginheight="0" scrolling="no"></iframe>
</div></figure>



<figure class="wp-block-image size-large"><a href="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1.png"><img loading="lazy" width="300" height="300" data-attachment-id="34429" data-permalink="https://newdrugapprovals.org/2026/11/18/34428/str1-585/" data-orig-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1.png" data-orig-size="300,300" data-comments-opened="1" data-image-title="STR1" data-image-description="" data-image-caption="" data-large-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1.png?w=300" src="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1.png?w=300" alt="" class="wp-image-34429" srcset="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1.png 300w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str1.png?w=150 150w" sizes="auto, (max-width: 300px) 100vw, 300px" /></a></figure>



<figure class="wp-block-image size-large is-resized"><a href="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-5.jpg"><img loading="lazy" width="1018" height="1024" data-attachment-id="34430" data-permalink="https://newdrugapprovals.org/2026/11/18/34428/str2-88/" data-orig-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-5.jpg" data-orig-size="1102,1109" data-comments-opened="1" data-image-title="STR2" data-image-description="" data-image-caption="" data-large-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-5.jpg?w=500" src="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-5.jpg?w=1018" alt="" class="wp-image-34430" style="aspect-ratio:0.9931829518372776;width:529px;height:auto" srcset="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-5.jpg?w=1018 1018w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-5.jpg?w=150 150w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-5.jpg?w=298 298w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-5.jpg?w=768 768w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-5.jpg 1102w" sizes="auto, (max-width: 1018px) 100vw, 1018px" /></a></figure>
]]></content:encoded>
					
					<wfw:commentRss>https://newdrugapprovals.org/2026/11/18/34428/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">34428</post-id>
		<media:content url="https://2.gravatar.com/avatar/569350c7858a75cbcaa674b4e28141525334a91c696621375b3bfee581907c13?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">amcrasto</media:title>
		</media:content>

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1.png?w=300" medium="image" />

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-5.jpg?w=1018" medium="image" />
	</item>
		<item>
		<title>PIMICOTINIB</title>
		<link>https://newdrugapprovals.org/2026/11/17/pimicotinib-2/</link>
					<comments>https://newdrugapprovals.org/2026/11/17/pimicotinib-2/#respond</comments>
		
		<dc:creator><![CDATA[DR ANTHONY MELVIN CRASTO Ph.D]]></dc:creator>
		<pubDate>Tue, 17 Nov 2026 02:59:56 +0000</pubDate>
				<category><![CDATA[APPROVALS 2026]]></category>
		<category><![CDATA[FDA 2026]]></category>
		<category><![CDATA[Abbisko Therapeutics]]></category>
		<category><![CDATA[ABSK 021]]></category>
		<category><![CDATA[ABSK 021-7]]></category>
		<category><![CDATA[ABSK 021NX]]></category>
		<category><![CDATA[ASYM 133040]]></category>
		<category><![CDATA[HV1XI8HST2]]></category>
		<category><![CDATA[PIMICOTINIB]]></category>
		<category><![CDATA[Pimjetmi]]></category>
		<guid isPermaLink="false">http://newdrugapprovals.org/?p=34408</guid>

					<description><![CDATA[]]></description>
										<content:encoded><![CDATA[
<figure class="wp-block-embed is-type-wp-embed is-provider-new-drug-approvals wp-block-embed-new-drug-approvals"><div class="wp-block-embed__wrapper">
<blockquote class="wp-embedded-content" data-secret="4wuPKBdKgF"><a href="https://newdrugapprovals.org/2025/07/08/pimicotinib/">PIMICOTINIB</a></blockquote><iframe loading="lazy" class="wp-embedded-content" sandbox="allow-scripts" security="restricted"  title="&#8220;PIMICOTINIB&#8221; &#8212; New Drug Approvals" src="https://newdrugapprovals.org/2025/07/08/pimicotinib/embed/#?secret=XYJNj32fsm#?secret=4wuPKBdKgF" data-secret="4wuPKBdKgF" width="500" height="282" frameborder="0" marginwidth="0" marginheight="0" scrolling="no"></iframe>
</div></figure>



<figure class="wp-block-image size-large is-resized"><a href="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-9.jpg"><img loading="lazy" width="551" height="540" data-attachment-id="34409" data-permalink="https://newdrugapprovals.org/2026/11/17/pimicotinib-2/str1-583/" data-orig-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-9.jpg" data-orig-size="551,540" data-comments-opened="1" data-image-title="STR1" data-image-description="" data-image-caption="" data-large-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-9.jpg?w=500" src="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-9.jpg?w=551" alt="" class="wp-image-34409" style="width:332px;height:auto" srcset="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-9.jpg 551w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-9.jpg?w=150 150w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-9.jpg?w=300 300w" sizes="auto, (max-width: 551px) 100vw, 551px" /></a></figure>



<figure class="wp-block-image size-large is-resized"><a href="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-4.jpg"><img loading="lazy" width="881" height="749" data-attachment-id="34410" data-permalink="https://newdrugapprovals.org/2026/11/17/pimicotinib-2/str2-86/" data-orig-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-4.jpg" data-orig-size="881,749" data-comments-opened="1" data-image-title="STR2" data-image-description="" data-image-caption="" data-large-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-4.jpg?w=500" src="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-4.jpg?w=881" alt="" class="wp-image-34410" style="aspect-ratio:1.1762646595483983;width:584px;height:auto" srcset="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-4.jpg 881w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-4.jpg?w=150 150w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-4.jpg?w=300 300w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-4.jpg?w=768 768w" sizes="auto, (max-width: 881px) 100vw, 881px" /></a></figure>
]]></content:encoded>
					
					<wfw:commentRss>https://newdrugapprovals.org/2026/11/17/pimicotinib-2/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">34408</post-id>
		<media:content url="https://2.gravatar.com/avatar/569350c7858a75cbcaa674b4e28141525334a91c696621375b3bfee581907c13?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">amcrasto</media:title>
		</media:content>

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-9.jpg?w=551" medium="image" />

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-4.jpg?w=881" medium="image" />
	</item>
		<item>
		<title>Zamzetoclax</title>
		<link>https://newdrugapprovals.org/2026/11/16/zamzetoclax-2/</link>
					<comments>https://newdrugapprovals.org/2026/11/16/zamzetoclax-2/#respond</comments>
		
		<dc:creator><![CDATA[DR ANTHONY MELVIN CRASTO Ph.D]]></dc:creator>
		<pubDate>Mon, 16 Nov 2026 02:29:26 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<guid isPermaLink="false">http://newdrugapprovals.org/?p=34381</guid>

					<description><![CDATA[]]></description>
										<content:encoded><![CDATA[
<figure class="wp-block-embed is-type-wp-embed is-provider-new-drug-approvals wp-block-embed-new-drug-approvals"><div class="wp-block-embed__wrapper">
<blockquote class="wp-embedded-content" data-secret="ohlFHR4asy"><a href="https://newdrugapprovals.org/2025/12/16/zamzetoclax/">Zamzetoclax</a></blockquote><iframe loading="lazy" class="wp-embedded-content" sandbox="allow-scripts" security="restricted"  title="&#8220;Zamzetoclax&#8221; &#8212; New Drug Approvals" src="https://newdrugapprovals.org/2025/12/16/zamzetoclax/embed/#?secret=YYA0AJ4Rw4#?secret=ohlFHR4asy" data-secret="ohlFHR4asy" width="500" height="282" frameborder="0" marginwidth="0" marginheight="0" scrolling="no"></iframe>
</div></figure>



<figure class="wp-block-image size-large is-resized"><a href="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1.gif"><img loading="lazy" width="600" height="600" data-attachment-id="34382" data-permalink="https://newdrugapprovals.org/2026/11/16/zamzetoclax-2/str1-581/" data-orig-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1.gif" data-orig-size="600,600" data-comments-opened="1" data-image-title="STR1" data-image-description="" data-image-caption="" data-large-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1.gif?w=500" src="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1.gif?w=600" alt="" class="wp-image-34382" style="width:392px;height:auto" srcset="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1.gif 600w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str1.gif?w=150 150w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str1.gif?w=300 300w" sizes="auto, (max-width: 600px) 100vw, 600px" /></a></figure>
]]></content:encoded>
					
					<wfw:commentRss>https://newdrugapprovals.org/2026/11/16/zamzetoclax-2/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">34381</post-id>
		<media:content url="https://2.gravatar.com/avatar/569350c7858a75cbcaa674b4e28141525334a91c696621375b3bfee581907c13?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">amcrasto</media:title>
		</media:content>

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1.gif?w=600" medium="image" />
	</item>
		<item>
		<title>Zavolosotine</title>
		<link>https://newdrugapprovals.org/2026/11/15/zavolosotine-2/</link>
					<comments>https://newdrugapprovals.org/2026/11/15/zavolosotine-2/#respond</comments>
		
		<dc:creator><![CDATA[DR ANTHONY MELVIN CRASTO Ph.D]]></dc:creator>
		<pubDate>Sun, 15 Nov 2026 02:57:16 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<guid isPermaLink="false">http://newdrugapprovals.org/?p=34362</guid>

					<description><![CDATA[]]></description>
										<content:encoded><![CDATA[
<figure class="wp-block-embed is-type-wp-embed is-provider-new-drug-approvals wp-block-embed-new-drug-approvals"><div class="wp-block-embed__wrapper">
<blockquote class="wp-embedded-content" data-secret="1Gz7ZHkIuM"><a href="https://newdrugapprovals.org/2025/12/17/zavolosotine/">Zavolosotine</a></blockquote><iframe loading="lazy" class="wp-embedded-content" sandbox="allow-scripts" security="restricted"  title="&#8220;Zavolosotine&#8221; &#8212; New Drug Approvals" src="https://newdrugapprovals.org/2025/12/17/zavolosotine/embed/#?secret=Iu56mSUIqz#?secret=1Gz7ZHkIuM" data-secret="1Gz7ZHkIuM" width="500" height="282" frameborder="0" marginwidth="0" marginheight="0" scrolling="no"></iframe>
</div></figure>



<figure class="wp-block-image size-large is-resized"><a href="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-8.jpg"><img loading="lazy" width="847" height="730" data-attachment-id="34363" data-permalink="https://newdrugapprovals.org/2026/11/15/zavolosotine-2/str1-579/" data-orig-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-8.jpg" data-orig-size="847,730" data-comments-opened="1" data-image-title="STR1" data-image-description="" data-image-caption="" data-large-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-8.jpg?w=500" src="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-8.jpg?w=847" alt="" class="wp-image-34363" style="aspect-ratio:1.1602961172382535;width:405px;height:auto" srcset="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-8.jpg 847w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-8.jpg?w=150 150w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-8.jpg?w=300 300w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-8.jpg?w=768 768w" sizes="auto, (max-width: 847px) 100vw, 847px" /></a></figure>



<figure class="wp-block-image size-large is-resized"><a href="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-3.jpg"><img loading="lazy" width="800" height="1023" data-attachment-id="34364" data-permalink="https://newdrugapprovals.org/2026/11/15/zavolosotine-2/str2-84/" data-orig-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-3.jpg" data-orig-size="836,1070" data-comments-opened="1" data-image-title="STR2" data-image-description="" data-image-caption="" data-large-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-3.jpg?w=500" src="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-3.jpg?w=800" alt="" class="wp-image-34364" style="width:451px;height:auto" srcset="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-3.jpg?w=800 800w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-3.jpg?w=117 117w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-3.jpg?w=234 234w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-3.jpg?w=768 768w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-3.jpg 836w" sizes="auto, (max-width: 800px) 100vw, 800px" /></a></figure>
]]></content:encoded>
					
					<wfw:commentRss>https://newdrugapprovals.org/2026/11/15/zavolosotine-2/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">34362</post-id>
		<media:content url="https://2.gravatar.com/avatar/569350c7858a75cbcaa674b4e28141525334a91c696621375b3bfee581907c13?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">amcrasto</media:title>
		</media:content>

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-8.jpg?w=847" medium="image" />

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-3.jpg?w=800" medium="image" />
	</item>
		<item>
		<title>Zelenirstat</title>
		<link>https://newdrugapprovals.org/2026/11/14/zelenirstat-2/</link>
					<comments>https://newdrugapprovals.org/2026/11/14/zelenirstat-2/#respond</comments>
		
		<dc:creator><![CDATA[DR ANTHONY MELVIN CRASTO Ph.D]]></dc:creator>
		<pubDate>Sat, 14 Nov 2026 03:08:46 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<guid isPermaLink="false">http://newdrugapprovals.org/?p=34347</guid>

					<description><![CDATA[]]></description>
										<content:encoded><![CDATA[
<figure class="wp-block-embed is-type-wp-embed is-provider-new-drug-approvals wp-block-embed-new-drug-approvals"><div class="wp-block-embed__wrapper">
<blockquote class="wp-embedded-content" data-secret="61lgYpqrLO"><a href="https://newdrugapprovals.org/2025/12/18/zelenirstat/">Zelenirstat</a></blockquote><iframe loading="lazy" class="wp-embedded-content" sandbox="allow-scripts" security="restricted"  title="&#8220;Zelenirstat&#8221; &#8212; New Drug Approvals" src="https://newdrugapprovals.org/2025/12/18/zelenirstat/embed/#?secret=t33jY9DDmx#?secret=61lgYpqrLO" data-secret="61lgYpqrLO" width="500" height="282" frameborder="0" marginwidth="0" marginheight="0" scrolling="no"></iframe>
</div></figure>



<figure class="wp-block-image size-large"><a href="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-7.jpg"><img loading="lazy" width="1024" height="454" data-attachment-id="34348" data-permalink="https://newdrugapprovals.org/2026/11/14/zelenirstat-2/str1-577/" data-orig-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-7.jpg" data-orig-size="1211,537" data-comments-opened="1" data-image-title="STR1" data-image-description="" data-image-caption="" data-large-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-7.jpg?w=500" src="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-7.jpg?w=1024" alt="" class="wp-image-34348" srcset="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-7.jpg?w=1024 1024w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-7.jpg?w=150 150w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-7.jpg?w=300 300w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-7.jpg?w=768 768w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-7.jpg 1211w" sizes="auto, (max-width: 1024px) 100vw, 1024px" /></a></figure>



<figure class="wp-block-image size-large"><a href="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-2.jpg"><img loading="lazy" width="821" height="965" data-attachment-id="34349" data-permalink="https://newdrugapprovals.org/2026/11/14/zelenirstat-2/str2-82/" data-orig-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-2.jpg" data-orig-size="821,965" data-comments-opened="1" data-image-title="STR2" data-image-description="" data-image-caption="" data-large-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-2.jpg?w=500" src="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-2.jpg?w=821" alt="" class="wp-image-34349" srcset="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-2.jpg 821w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-2.jpg?w=128 128w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-2.jpg?w=255 255w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-2.jpg?w=768 768w" sizes="auto, (max-width: 821px) 100vw, 821px" /></a></figure>
]]></content:encoded>
					
					<wfw:commentRss>https://newdrugapprovals.org/2026/11/14/zelenirstat-2/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">34347</post-id>
		<media:content url="https://2.gravatar.com/avatar/569350c7858a75cbcaa674b4e28141525334a91c696621375b3bfee581907c13?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">amcrasto</media:title>
		</media:content>

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-7.jpg?w=1024" medium="image" />

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-2.jpg?w=821" medium="image" />
	</item>
		<item>
		<title>Zemirciclib</title>
		<link>https://newdrugapprovals.org/2026/11/13/zemirciclib-2/</link>
					<comments>https://newdrugapprovals.org/2026/11/13/zemirciclib-2/#respond</comments>
		
		<dc:creator><![CDATA[DR ANTHONY MELVIN CRASTO Ph.D]]></dc:creator>
		<pubDate>Fri, 13 Nov 2026 02:46:12 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<guid isPermaLink="false">http://newdrugapprovals.org/?p=34333</guid>

					<description><![CDATA[]]></description>
										<content:encoded><![CDATA[
<figure class="wp-block-embed is-type-wp-embed is-provider-new-drug-approvals wp-block-embed-new-drug-approvals"><div class="wp-block-embed__wrapper">
<blockquote class="wp-embedded-content" data-secret="WMu9ZU6wcN"><a href="https://newdrugapprovals.org/2025/12/19/zemirciclib/">Zemirciclib</a></blockquote><iframe loading="lazy" class="wp-embedded-content" sandbox="allow-scripts" security="restricted"  title="&#8220;Zemirciclib&#8221; &#8212; New Drug Approvals" src="https://newdrugapprovals.org/2025/12/19/zemirciclib/embed/#?secret=QrrZU4YEz0#?secret=WMu9ZU6wcN" data-secret="WMu9ZU6wcN" width="500" height="282" frameborder="0" marginwidth="0" marginheight="0" scrolling="no"></iframe>
</div></figure>



<figure class="wp-block-image size-large"><a href="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-6.jpg"><img loading="lazy" width="297" height="352" data-attachment-id="34336" data-permalink="https://newdrugapprovals.org/2026/11/13/zemirciclib-2/str1-575/" data-orig-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-6.jpg" data-orig-size="297,352" data-comments-opened="1" data-image-title="STR1" data-image-description="" data-image-caption="" data-large-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-6.jpg?w=297" src="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-6.jpg?w=297" alt="" class="wp-image-34336" srcset="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-6.jpg 297w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-6.jpg?w=127 127w" sizes="auto, (max-width: 297px) 100vw, 297px" /></a></figure>
]]></content:encoded>
					
					<wfw:commentRss>https://newdrugapprovals.org/2026/11/13/zemirciclib-2/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">34333</post-id>
		<media:content url="https://2.gravatar.com/avatar/569350c7858a75cbcaa674b4e28141525334a91c696621375b3bfee581907c13?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">amcrasto</media:title>
		</media:content>

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-6.jpg?w=297" medium="image" />
	</item>
		<item>
		<title>Asundexian</title>
		<link>https://newdrugapprovals.org/2026/11/12/asundexian/</link>
					<comments>https://newdrugapprovals.org/2026/11/12/asundexian/#respond</comments>
		
		<dc:creator><![CDATA[DR ANTHONY MELVIN CRASTO Ph.D]]></dc:creator>
		<pubDate>Thu, 12 Nov 2026 02:39:01 +0000</pubDate>
				<category><![CDATA[APPROVALS 2026]]></category>
		<category><![CDATA[FDA 2026]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<guid isPermaLink="false">http://newdrugapprovals.org/?p=34255</guid>

					<description><![CDATA[Asundexian CAS 2064121-65-7 MW 592.9 g/mol, C26H21ClF4N6O4 4-[[(2S)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxo-1-pyridinyl]butanoyl]amino]-2-fluorobenzamide (S)-4-(2-(4-(5-Chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-methoxy-2-oxopyridin-1(2H)-yl)butanamido)-2-fluorobenzamide 4-[[(2~{S})-2-[4-[5-chloranyl-2-[4-(trifluoromethyl)-1,2,3-triazol-1-yl]phenyl]-5-methoxy-2-oxidanylidene-pyridin-1-yl]butanoyl]amino]-2-fluoranyl-benzamide (S)-4-[2-[4-[5-Chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl]butanamido]-2-fluorobenzamide APPROVALS 2026, FDA 2026, Sunharbo, LA585UM8DE, BAY2433334, BAY 2433334 To reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack Asundexian, sold under the brand name Sunharbo, is a Factor XIa inhibitor developed by &#8230; <a href="https://newdrugapprovals.org/2026/11/12/asundexian/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
										<content:encoded><![CDATA[
<figure class="wp-block-image size-large"><a href="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-5.jpg"><img loading="lazy" width="1024" height="562" data-attachment-id="34257" data-permalink="https://newdrugapprovals.org/2026/11/12/asundexian/str1-573/" data-orig-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-5.jpg" data-orig-size="1347,740" data-comments-opened="1" data-image-title="STR1" data-image-description="" data-image-caption="" data-large-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-5.jpg?w=500" src="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-5.jpg?w=1024" alt="" class="wp-image-34257" srcset="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-5.jpg?w=1024 1024w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-5.jpg?w=150 150w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-5.jpg?w=300 300w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-5.jpg?w=768 768w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-5.jpg 1347w" sizes="auto, (max-width: 1024px) 100vw, 1024px" /></a></figure>



<figure class="wp-block-image size-large"><a href="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1.jpg"><img loading="lazy" width="407" height="357" data-attachment-id="34260" data-permalink="https://newdrugapprovals.org/2026/11/12/asundexian/s1-78/" data-orig-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1.jpg" data-orig-size="407,357" data-comments-opened="1" data-image-title="S1" data-image-description="" data-image-caption="" data-large-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1.jpg?w=407" src="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1.jpg?w=407" alt="" class="wp-image-34260" srcset="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1.jpg 407w, https://newdrugapprovals.org/wp-content/uploads/2026/11/s1.jpg?w=150 150w, https://newdrugapprovals.org/wp-content/uploads/2026/11/s1.jpg?w=300 300w" sizes="auto, (max-width: 407px) 100vw, 407px" /></a></figure>



<p class="wp-block-paragraph">Asundexian</p>



<p class="wp-block-paragraph">CAS 2064121-65-7</p>



<p class="wp-block-paragraph">MW 592.9 g/mol, <a href="https://pubchem.ncbi.nlm.nih.gov/#query=C26H21ClF4N6O4">C<sub>26</sub>H<sub>21</sub>ClF<sub>4</sub>N<sub>6</sub>O<sub>4</sub></a></p>



<p class="wp-block-paragraph">4-[[(2<em>S</em>)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxo-1-pyridinyl]butanoyl]amino]-2-fluorobenzamide</p>



<ul class="wp-block-list">
<li><a href="https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22(S)-4-(2-(4-(5-Chloro-2-(4-(trifluoromethyl)-1H-1%2C2%2C3-triazol-1-yl)phenyl)-5-methoxy-2-oxopyridin-1(2H)-yl)butanamido)-2-fluorobenzamide%22[CompleteSynonym]%20AND%20135206011[StandardizedCID]" target="_blank" rel="noopener">(S)-4-(2-(4-(5-Chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-methoxy-2-oxopyridin-1(2H)-yl)butanamido)-2-fluorobenzamide</a></li>



<li><a href="https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%224-%5B%5B(2~%7BS%7D)-2-%5B4-%5B5-chloranyl-2-%5B4-(trifluoromethyl)-1%2C2%2C3-triazol-1-yl%5Dphenyl%5D-5-methoxy-2-oxidanylidene-pyridin-1-yl%5Dbutanoyl%5Damino%5D-2-fluoranyl-benzamide%22[CompleteSynonym]%20AND%20135206011[StandardizedCID]" target="_blank" rel="noopener">4-[[(2~{S})-2-[4-[5-chloranyl-2-[4-(trifluoromethyl)-1,2,3-triazol-1-yl]phenyl]-5-methoxy-2-oxidanylidene-pyridin-1-yl]butanoyl]amino]-2-fluoranyl-benzamide</a></li>



<li><a href="https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22(S)-4-%5B2-%5B4-%5B5-Chloro-2-%5B4-(trifluoromethyl)-1H-1%2C2%2C3-triazol-1-yl%5Dphenyl%5D-5-methoxy-2-oxopyridin-1(2H)-yl%5Dbutanamido%5D-2-fluorobenzamide%22[CompleteSynonym]%20AND%20135206011[StandardizedCID]" target="_blank" rel="noopener">(S)-4-[2-[4-[5-Chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl]butanamido]-2-fluorobenzamide</a></li>
</ul>



<p class="wp-block-paragraph">APPROVALS 2026, FDA 2026, Sunharbo, LA585UM8DE, <a href="https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22BAY2433334%22[CompleteSynonym]%20AND%20135206011[StandardizedCID]" target="_blank" rel="noopener">BAY2433334</a>, <a href="https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22BAY2433334%22[CompleteSynonym]%20AND%20135206011[StandardizedCID]" target="_blank" rel="noopener">BAY 2433334</a></p>



<p class="wp-block-paragraph">To reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack</p>



<p class="wp-block-paragraph"><strong>Asundexian</strong>, sold under the brand name <strong>Sunharbo</strong>, is a <a href="https://en.wikipedia.org/wiki/Factor_XI">Factor XIa</a> inhibitor developed by <a href="https://en.wikipedia.org/wiki/Bayer">Bayer</a> to prevent stroke.<sup><a href="https://en.wikipedia.org/wiki/Asundexian#cite_note-1">[1]</a></sup><sup><a href="https://en.wikipedia.org/wiki/Asundexian#cite_note-2">[2]</a></sup></p>



<h2 class="wp-block-heading">Clinical trials</h2>



<p class="wp-block-paragraph">Asundexian efficacy and safety in patients have been evaluated in two clinical trial programs: phase IIb PACIFIC and phase III OCEANIC.<sup><a href="https://en.wikipedia.org/wiki/Asundexian#cite_note-:0-3">[3]</a></sup> In the phase IIb PACIFIC clinical trial programs, asundexian consistently showed no difference in bleeding rate compared with placebo<sup><a href="https://en.wikipedia.org/wiki/Asundexian#cite_note-4">[4]</a></sup><sup><a href="https://en.wikipedia.org/wiki/Asundexian#cite_note-5">[5]</a></sup> and reduced the risk of bleeding compared with <a href="https://en.wikipedia.org/wiki/Apixaban">apixaban</a>.<sup><a href="https://en.wikipedia.org/wiki/Asundexian#cite_note-6">[6]</a></sup> All three trials in the programs were not powered to show efficacy of asundexian.<sup><a href="https://en.wikipedia.org/wiki/Asundexian#cite_note-:0-3">[3]</a></sup> However, a phase III trial, OCEANIC-AF, demonstrated a hazard ratio of 3.8 for stroke or systemic embolism with asundexian vs apixaban, so it was stopped due to a &#8220;lack of efficacy.&#8221; The remaining active study OCEANIC-STROKE was recommended to continue as planned. Bayer is reevaluating the design of the OCEANIC-AFINA based on the findings of the OCEANIC trial.<sup><a href="https://en.wikipedia.org/wiki/Asundexian#cite_note-7">[7]</a></sup></p>



<p class="wp-block-paragraph">In February 2026, the OCEANIC-STROKE trial was completed. This was a multicentre, randomised, double-blind, placebo-controlled study involving 12,000 people worldwide who had suffered a non-cardioembolic ischaemic stroke or a transient ischaemic attack. The trial revealed a 26% reduction in the rate of recurrence without major bleeding, a typical complication of antithrombotic drugs.<sup><a href="https://en.wikipedia.org/wiki/Asundexian#cite_note-8">[8]</a></sup><sup><a href="https://en.wikipedia.org/wiki/Asundexian#cite_note-9">[9]</a></sup><sup><a href="https://en.wikipedia.org/wiki/Asundexian#cite_note-10">[10]</a></sup></p>



<p class="wp-block-paragraph">SYN</p>



<p class="wp-block-paragraph"><a href="https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22US10421742%2C%20Example%20235%22[CompleteSynonym]%20AND%20135206011[StandardizedCID]" target="_blank" rel="noopener">US10421742, </a></p>



<p class="wp-block-paragraph">US20180194745 &#8211; Substituted oxopyridine derivatives</p>



<h2 class="wp-block-heading">Example 235</h2>



<h2 class="wp-block-heading">4-({(2S)-2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluorobenzamide (Enantiomer 2)</h2>



<figure class="wp-block-image size-large"><a href="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-1.jpg"><img loading="lazy" width="382" height="217" data-attachment-id="34280" data-permalink="https://newdrugapprovals.org/2026/11/12/asundexian/s1-79/" data-orig-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-1.jpg" data-orig-size="382,217" data-comments-opened="1" data-image-title="S1" data-image-description="" data-image-caption="" data-large-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-1.jpg?w=382" src="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-1.jpg?w=382" alt="" class="wp-image-34280" srcset="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-1.jpg 382w, https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-1.jpg?w=150 150w, https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-1.jpg?w=300 300w" sizes="auto, (max-width: 382px) 100vw, 382px" /></a></figure>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td><a></a>Enantiomer separation of 63 mg of 4-({2-[4-{5-chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluorobenzamide (racemate) gave 25 mg of enantiomer 1 (chiral HPLC: R <sub>t</sub>=2.6 min) and 26 mg of the title compound (enantiomer 2): chiral HPLC: R <sub>t</sub>=3.6 min; 100% ee.</td></tr></tbody></table></figure>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td><a></a>Separating method: column: Chiralpak AD-H SFC, 5 μm 250 mm×20 mm; mobile phase: carbon dioxide 75%/ethanol 25%; temperature: 40° C.; flow rate: 80 ml/min; pressure: 100 bar; UV detection: 210 nm.</td></tr></tbody></table></figure>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td><a></a>Analysis: column: Daicel AD SFC 3 μm, 100 mm×4.6 mm; mobile phase: 75% carbon dioxide, 25% ethanol; flow rate: 3 ml/min; UV detection: 210 nm.</td></tr></tbody></table></figure>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td><a></a>LC-MS [Method 1]: R <sub>t</sub>=0.92 min; MS (ESIpos): m/z=593 [M+H] <sup>+</sup></td></tr></tbody></table></figure>



<p class="wp-block-paragraph">SYN1</p>



<p class="wp-block-paragraph">MEDKOO</p>



<h3 class="wp-block-heading">Synthetic Reference</h3>



<p class="wp-block-paragraph">Design and Preclinical Characterization Program toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders</p>



<p class="wp-block-paragraph">By:&nbsp;Roehrig, Susanne; et al</p>



<p class="wp-block-paragraph">Journal of Medicinal Chemistry (2023), 66(17), 12203-12224</p>



<figure class="wp-block-image size-large"><a href="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-4.jpg"><img loading="lazy" width="1024" height="559" data-attachment-id="34290" data-permalink="https://newdrugapprovals.org/2026/11/12/asundexian/s1-82/" data-orig-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-4.jpg" data-orig-size="1166,637" data-comments-opened="1" data-image-title="S1" data-image-description="" data-image-caption="" data-large-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-4.jpg?w=500" src="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-4.jpg?w=1024" alt="" class="wp-image-34290" srcset="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-4.jpg?w=1024 1024w, https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-4.jpg?w=150 150w, https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-4.jpg?w=300 300w, https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-4.jpg?w=768 768w, https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-4.jpg 1166w" sizes="auto, (max-width: 1024px) 100vw, 1024px" /></a></figure>



<p class="wp-block-paragraph">SYN2</p>



<h3 class="wp-block-heading">Synthetic Reference</h3>



<p class="wp-block-paragraph">Study on Preparation Process of Anticoagulant BAY2433334</p>



<p class="wp-block-paragraph">By:&nbsp;Zeng, Yanqun; et al</p>



<p class="wp-block-paragraph">Molecules (2024), 29(24), 6039</p>



<figure class="wp-block-image size-large"><a href="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-3.jpg"><img loading="lazy" width="1024" height="444" data-attachment-id="34289" data-permalink="https://newdrugapprovals.org/2026/11/12/asundexian/s1-81/" data-orig-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-3.jpg" data-orig-size="1087,472" data-comments-opened="1" data-image-title="S1" data-image-description="" data-image-caption="" data-large-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-3.jpg?w=500" src="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-3.jpg?w=1024" alt="" class="wp-image-34289" srcset="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-3.jpg?w=1024 1024w, https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-3.jpg?w=150 150w, https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-3.jpg?w=300 300w, https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-3.jpg?w=768 768w, https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-3.jpg 1087w" sizes="auto, (max-width: 1024px) 100vw, 1024px" /></a></figure>



<p class="wp-block-paragraph">SYN3</p>



<h3 class="wp-block-heading">Synthetic Reference</h3>



<p class="wp-block-paragraph">Preparation of triazole containing oxopyridine derivative and its application in medicine</p>



<p class="wp-block-paragraph">Assignee:&nbsp;Tianjin Institute of Pharmaceutical Research Co., Ltd.</p>



<p class="wp-block-paragraph">Inventors:&nbsp;Wei, Qunchao; et al</p>



<p class="wp-block-paragraph">China</p>



<p class="wp-block-paragraph">Patent#CN116903585 A</p>



<figure class="wp-block-image size-large"><a href="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-2.jpg"><img loading="lazy" width="1024" height="556" data-attachment-id="34286" data-permalink="https://newdrugapprovals.org/2026/11/12/asundexian/s1-80/" data-orig-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-2.jpg" data-orig-size="1131,615" data-comments-opened="1" data-image-title="S1" data-image-description="" data-image-caption="" data-large-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-2.jpg?w=500" src="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-2.jpg?w=1024" alt="" class="wp-image-34286" srcset="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-2.jpg?w=1024 1024w, https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-2.jpg?w=150 150w, https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-2.jpg?w=300 300w, https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-2.jpg?w=768 768w, https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-2.jpg 1131w" sizes="auto, (max-width: 1024px) 100vw, 1024px" /></a></figure>



<p class="wp-block-paragraph">SYN REF</p>



<ul class="wp-block-list">
<li><a href="https://pubmed.ncbi.nlm.nih.gov/40010270">Discovery of potent, highly selective, and orally bioavailable factor XIa inhibitors for anticoagulant therapy</a>Publication Name:European Journal of Medicinal ChemistryPublication Date:2025-05-05PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40010270">40010270</a>DOI:<a href="https://doi.org/10.1016/j.ejmech.2025.117436">10.1016/j.ejmech.2025.117436</a></li>



<li><a href="https://pubmed.ncbi.nlm.nih.gov/39580913">Discovery of potent and selective factor XIa inhibitors incorporating triazole-based benzoic acid as novel P2’ fragments: Molecular dynamics simulations and anticoagulant activity</a>Publication Name:European Journal of Medicinal ChemistryPublication Date:2025-01-15PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39580913">39580913</a>DOI:<a href="https://doi.org/10.1016/j.ejmech.2024.117067">10.1016/j.ejmech.2024.117067</a></li>



<li><a href="https://pubmed.ncbi.nlm.nih.gov/38211702">Design, synthesis and biological evaluation of 6-chloro-quinolin-2-one derivatives as novel FXIa inhibitors</a>Publication Name:Bioorganic &amp; Medicinal Chemistry LettersPublication Date:2024-02-01PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38211702">38211702</a>DOI:<a href="https://doi.org/10.1016/j.bmcl.2024.129610">10.1016/j.bmcl.2024.129610</a></li>



<li><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510402">Design and Preclinical Characterization Program toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders</a>Publication Name:Journal of Medicinal ChemistryPublication Date:2023-09-05PMCID:<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510402">PMC10510402</a>PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37669040">37669040</a>DOI:<a href="https://doi.org/10.1021/acs.jmedchem.3c00795">10.1021/acs.jmedchem.3c00795</a></li>



<li><a href="https://pubmed.ncbi.nlm.nih.gov/37037122">Factor XIa Inhibitors in Anticoagulation Therapy: Recent Advances and Perspectives</a>Publication Name:Journal of Medicinal ChemistryPublication Date:2023-04-10PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37037122">37037122</a>DOI:<a href="https://doi.org/10.1021/acs.jmedchem.2c02130">10.1021/acs.jmedchem.2c02130</a></li>
</ul>



<p class="wp-block-paragraph">Pat</p>



<ul class="wp-block-list">
<li><a href="https://pubchem.ncbi.nlm.nih.gov/patent/DE-522201-C">Process for the preparation of monoazo dyes</a>Publication Number:<a href="https://pubchem.ncbi.nlm.nih.gov/patent/DE-522201-C">DE-522201-C</a>Priority Date:1928-05-15Grant Date:1931-04-01, Publication Number:<a href="https://pubchem.ncbi.nlm.nih.gov/patent/BE-638782-A">BE-638782-A</a>, Publication Number:<a href="https://pubchem.ncbi.nlm.nih.gov/patent/BE-625897-A">BE-625897-A</a>, Publication Number:<a href="https://pubchem.ncbi.nlm.nih.gov/patent/BE-499305-A">BE-499305-A</a></li>
</ul>



<ul class="wp-block-list">
<li><a href="https://pubchem.ncbi.nlm.nih.gov/patent/US-3959322-A">Synthesis of 13-alkyl-gon-4-ones</a>Publication Number:<a href="https://pubchem.ncbi.nlm.nih.gov/patent/US-3959322-A">US-3959322-A</a>Priority Date:1960-09-22Grant Date:1976-05-25</li>



<li><a href="https://pubchem.ncbi.nlm.nih.gov/patent/DE-1124412-B">Self-supporting explosives mixture that can be deformed into foils and other structures</a>Publication Number:<a href="https://pubchem.ncbi.nlm.nih.gov/patent/DE-1124412-B">DE-1124412-B</a>Priority Date:1960-08-17</li>



<li><a href="https://pubchem.ncbi.nlm.nih.gov/patent/DE-1445151-A1">Process for the production of chemical compounds</a>Publication Number:<a href="https://pubchem.ncbi.nlm.nih.gov/patent/DE-1445151-A1">DE-1445151-A1</a>Priority Date:1959-09-25</li>



<li><a href="https://pubchem.ncbi.nlm.nih.gov/patent/US-2907740-A">Polyepoxide diphenolic acid amide compositions and said compositions modified with aldehyde condensates</a>Publication Number:<a href="https://pubchem.ncbi.nlm.nih.gov/patent/US-2907740-A">US-2907740-A</a>Priority Date:1958-10-14Grant Date:1959-10-06</li>



<li><a href="https://pubchem.ncbi.nlm.nih.gov/patent/DE-933864-C">Process for the production of alcohols</a>Publication Number:<a href="https://pubchem.ncbi.nlm.nih.gov/patent/DE-933864-C">DE-933864-C</a></li>
</ul>



<h2 class="wp-block-heading">References</h2>



<ol id="mwQA" class="wp-block-list">
<li><a href="https://en.wikipedia.org/wiki/Asundexian#cite_ref-1"></a> Heitmeier, Stefan; Visser, Mayken; Tersteegen, Adrian; Dietze-Torres, Julia; Glunz, Julia; Gerdes, Christoph; Laux, Volker; Stampfuss, Jan; Roehrig, Susanne (June 2022). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313898">&#8220;Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa&#8221;</a>. <em>Journal of Thrombosis and Haemostasis</em>. <strong>20</strong> (6): 1400–1411. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)">doi</a>:<a href="https://doi.org/10.1111%2Fjth.15700">10.1111/jth.15700</a>. <a href="https://en.wikipedia.org/wiki/PMC_(identifier)">PMC</a> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313898">9313898</a>. <a href="https://en.wikipedia.org/wiki/PMID_(identifier)">PMID</a> <a href="https://pubmed.ncbi.nlm.nih.gov/35289054">35289054</a>.</li>



<li><a href="https://en.wikipedia.org/wiki/Asundexian#cite_ref-2"></a> Roehrig, Susanne; Ackerstaff, Jens; Jiménez Núñez, Eloísa; Teller, Henrik; Ellerbrock, Pascal; Meier, Katharina; Heitmeier, Stefan; Tersteegen, Adrian; Stampfuss, Jan; Lang, Dieter; Schlemmer, Karl-Heinz; Schaefer, Martina; Gericke, Kersten M.; Kinzel, Tom; Meibom, Daniel (2023-09-05). <a href="https://doi.org/10.1021/acs.jmedchem.3c00795">&#8220;Design and Preclinical Characterization Program toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders&#8221;</a>. <em>Journal of Medicinal Chemistry</em>. <strong>66</strong> (17): 12203–12224. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)">doi</a>:<a href="https://doi.org/10.1021%2Facs.jmedchem.3c00795">10.1021/acs.jmedchem.3c00795</a>. <a href="https://en.wikipedia.org/wiki/ISSN_(identifier)">ISSN</a> <a href="https://search.worldcat.org/issn/0022-2623">0022-2623</a>. <a href="https://en.wikipedia.org/wiki/PMC_(identifier)">PMC</a> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510402">10510402</a>. <a href="https://en.wikipedia.org/wiki/PMID_(identifier)">PMID</a> <a href="https://pubmed.ncbi.nlm.nih.gov/37669040">37669040</a>.</li>



<li><a href="https://en.wikipedia.org/wiki/Asundexian#cite_ref-:0_3-0"></a><a href="https://en.wikipedia.org/wiki/Asundexian#cite_ref-:0_3-1"></a> <a href="https://www.bayer.com/media/en-us/bayer-initiates-landmark-phase-iii-study-program-to-investigate-oral-fxia-inhibitor-asundexian/">&#8220;Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian&#8221;</a>. <em>Bayer</em> (Press release). 2022-08-28. Retrieved 2023-12-27.</li>



<li><a href="https://en.wikipedia.org/wiki/Asundexian#cite_ref-4"></a> <a href="https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2022/08/27/04/10/http%3a%2f%2fwww.acc.org%2fLatest-in-Cardiology%2fClinical-Trials%2f2022%2f08%2f27%2f04%2f10%2fPACIFIC-STROKE">&#8220;AntiCoagulation via Inhibition of FXIa by the Oral Compound BAY 2433334 – Non-cardioembolic Stroke&#8221;</a>. <em>American College of Cardiology</em>. Retrieved 2023-12-26.</li>



<li><a href="https://en.wikipedia.org/wiki/Asundexian#cite_ref-5"></a> Rao, Sunil V.; Kirsch, Bodo; Bhatt, Deepak L.; Budaj, Andrzej; Coppolecchia, Rosa; Eikelboom, John; James, Stefan K.; Jones, W. Schuyler; Merkely, Bela; Keller, Lars; Hermanides, Renicus S.; Campo, Gianluca; Ferreiro, José Luis; Shibasaki, Taro; Mundl, Hardi (2022-10-18). <a href="https://doi.org/10.1161%2FCIRCULATIONAHA.122.061612">&#8220;A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction&#8221;</a>. <em>Circulation</em>. <strong>146</strong> (16): 1196–1206. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)">doi</a>:<a href="https://doi.org/10.1161%2FCIRCULATIONAHA.122.061612">10.1161/CIRCULATIONAHA.122.061612</a>. <a href="https://en.wikipedia.org/wiki/Hdl_(identifier)">hdl</a>:<a href="https://hdl.handle.net/11392%2F2520330">11392/2520330</a>. <a href="https://en.wikipedia.org/wiki/ISSN_(identifier)">ISSN</a> <a href="https://search.worldcat.org/issn/0009-7322">0009-7322</a>. <a href="https://en.wikipedia.org/wiki/PMID_(identifier)">PMID</a> <a href="https://pubmed.ncbi.nlm.nih.gov/36030390">36030390</a>.</li>



<li><a href="https://en.wikipedia.org/wiki/Asundexian#cite_ref-6"></a> <a href="https://www.acc.org/Latest-in-Cardiology/Articles/2022/06/17/11/54/http%3a%2f%2fwww.acc.org%2fLatest-in-Cardiology%2fArticles%2f2022%2f06%2f17%2f11%2f54%2fThe-Next-Wave-of-Anticoagulation">&#8220;The Next Wave of Anticoagulation: Results of PACIFIC-AF and the Future Role of Factor XIa Inhibition in Atrial Fibrillation&#8221;</a>. <em>American College of Cardiology</em>. Retrieved 2023-12-26.</li>



<li><a href="https://en.wikipedia.org/wiki/Asundexian#cite_ref-7"></a> <a href="https://www.bayer.com/media/en-us/oceanic-af-study-stopped-early-due-to-lack-of-efficacy/">&#8220;OCEANIC-AF study stopped early due to lack of efficacy&#8221;</a>. <em>Bayer</em> (Press release). 2023-11-19. Retrieved 2023-12-27.</li>



<li><a href="https://en.wikipedia.org/wiki/Asundexian#cite_ref-8"></a> Piccini, Jonathan P.; Patel, Manesh R.; Steffel, Jan; Ferdinand, Keith; Van Gelder, Isabelle C.; Russo, Andrea M.; Ma, Chang-Sheng; Goodman, Shaun G.; Oldgren, Jonas; Hammett, Christopher; Lopes, Renato D.; Akao, Masaharu; De Caterina, Raffaele; Kirchhof, Paulus; Gorog, Diana A.; Hemels, Martin; Rienstra, Michiel; Jones, W. Schuyler; Harrington, Josephine; Lip, Gregory Y.H.; Ellis, Stephen J.; Rockhold, Frank W.; Neumann, Christoph; Alexander, John H.; Viethen, Thomas; Hung, James; Coppolecchia, Rosa; Mundl, Hardi; Caso, Valeria (2025). &#8220;Asundexian versus Apixaban in Patients with Atrial Fibrillation&#8221;. <em>New England Journal of Medicine</em>. <strong>392</strong> (1): 23–32. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)">doi</a>:<a href="https://doi.org/10.1056%2FNEJMoa2407105">10.1056/NEJMoa2407105</a>. <a href="https://en.wikipedia.org/wiki/Hdl_(identifier)">hdl</a>:<a href="https://hdl.handle.net/2066%2F315752">2066/315752</a>. <a href="https://en.wikipedia.org/wiki/PMID_(identifier)">PMID</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39225267">39225267</a>.</li>



<li><a href="https://en.wikipedia.org/wiki/Asundexian#cite_ref-9"></a> <a href="https://www.ausl.bologna.it/news/current/ictus-ischemico-i-risultati-della-ricerca-su-un-nuovo-farmaco-sperimentale-recidive-ridotte-del-26">&#8220;Ictus ischemico, i risultati della ricerca su un nuovo farmaco sperimentale: recidive ridotte del 26%&#8221;</a>. <em><a href="https://en.wikipedia.org/wiki/Ospedale_Maggiore_di_Bologna">Ospedale Maggiore di Bologna</a></em> (in Italian).</li>



<li><a href="https://en.wikipedia.org/wiki/Asundexian#cite_ref-10"></a> <a href="https://www.bayer.com/en/us/news-stories/asundexian-after-a-non-cardioembolic-ischemic-stroke">&#8220;Bayer&#8217;s asundexian demonstrated a substantial 26% reduction in stroke after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack, with no increase in ISTH major bleeding versus placebo&#8221;</a>. <em>Bayer</em>.</li>
</ol>



<p class="wp-block-paragraph"><strong>ADVERTISEMENT</strong></p>



<p class="wp-block-paragraph"><strong>ANAX LABORATORIES</strong></p>



<p class="wp-block-paragraph">WEBSITE <a href="https://www.anaxlab.com/">https://www.anaxlab.com/</a></p>



<p class="wp-block-paragraph"><a href="https://www.anaxlab.com/"><strong>Discovery Solutions</strong></a>, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences</p>



<p class="wp-block-paragraph"><a href="https://www.anaxlab.com/">Development Solutions</a>, Developing from Lab scale to PR&amp;D, Kilo Scale-ups and Commercial Scales</p>



<p class="wp-block-paragraph">SEE MORE&#8230;&#8230;&#8230;<a href="https://www.anaxlab.com/">Integrated Solutions</a>, <a href="https://www.anaxlab.com/">Manufacturing Solutions</a>, <a href="https://www.anaxlab.com/products">Products</a>,<br><a href="https://www.anaxlab.com/contact">Can&#8217;t Find? Let&#8217;s Connect</a></p>



<figure class="wp-block-image size-large is-resized"><a href="https://newdrugapprovals.org/wp-content/uploads/2026/11/image-11ac343d.png"><img loading="lazy" width="618" height="103" data-attachment-id="34298" data-permalink="https://newdrugapprovals.org/2026/11/12/asundexian/image-11ac343d/" data-orig-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/image-11ac343d.png" data-orig-size="618,103" data-comments-opened="1" data-image-title="image-11ac343d" data-image-description="" data-image-caption="" data-large-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/image-11ac343d.png?w=500" src="https://newdrugapprovals.org/wp-content/uploads/2026/11/image-11ac343d.png?w=618" alt="" class="wp-image-34298" style="aspect-ratio:5.96039603960396;width:602px;height:auto" srcset="https://newdrugapprovals.org/wp-content/uploads/2026/11/image-11ac343d.png 618w, https://newdrugapprovals.org/wp-content/uploads/2026/11/image-11ac343d.png?w=150 150w, https://newdrugapprovals.org/wp-content/uploads/2026/11/image-11ac343d.png?w=300 300w" sizes="auto, (max-width: 618px) 100vw, 618px" /></a></figure>



<p class="wp-block-paragraph"><a href="https://newdrugapprovals.org/wp-content/uploads/2026/01/image.png"></a></p>



<p class="wp-block-paragraph"><strong>Phone :</strong> +91&nbsp;897704 2010 / &nbsp;+91 9177075735, <strong>Email :</strong> <a href="mailto:info@anaxlab.com">info@anaxlab.com</a></p>



<p class="wp-block-paragraph"><a href="https://www.linkedin.com/search/results/all/?keywords=%23medicinalchemistry&amp;origin=HASH_TAG_FROM_FEED">#MedicinalChemistry</a>, <a href="https://www.linkedin.com/search/results/all/?keywords=%23drugdiscovery&amp;origin=HASH_TAG_FROM_FEED">#DrugDiscovery</a>, <a href="https://www.linkedin.com/search/results/all/?keywords=%23organicsynthesis&amp;origin=HASH_TAG_FROM_FEED">#OrganicSynthesis</a>, <a href="https://www.linkedin.com/search/results/all/?keywords=%23chemicallibrary&amp;origin=HASH_TAG_FROM_FEED&amp;lipi=urn%3Ali%3Apage%3Ad_flagship3_detail_base%3B7Nok72e6SI6pSENnVtf7gQ%3D%3D">#ChemicalLibrary</a>, <a href="https://www.linkedin.com/search/results/all/?keywords=%23buildingblocks&amp;origin=HASH_TAG_FROM_FEED">#BuildingBlocks</a>, <a href="https://www.linkedin.com/search/results/all/?keywords=%23sarstudies&amp;origin=HASH_TAG_FROM_FEED">#SARStudies</a>, <a href="https://www.linkedin.com/search/results/all/?keywords=%23chemistryinnovation&amp;origin=HASH_TAG_FROM_FEED">#ChemistryInnovation</a>, <a href="https://www.linkedin.com/search/results/all/?keywords=%23medchem&amp;origin=HASH_TAG_FROM_FEED">#medchem</a>, <a href="https://www.linkedin.com/search/results/all/?keywords=%23drugdevelopment&amp;origin=HASH_TAG_FROM_FEED">#Drugdevelopment</a>, <a href="https://www.linkedin.com/search/results/all/?keywords=%23biotech&amp;origin=HASH_TAG_FROM_FEED">#Biotech</a>, <a href="https://www.linkedin.com/search/results/all/?keywords=%23biotechnology&amp;origin=HASH_TAG_FROM_FEED">#Biotechnology</a>, <a href="https://www.linkedin.com/search/results/all/?keywords=%23anaxlaboratories&amp;origin=HASH_TAG_FROM_FEED">#AnaxLaboratories</a>, <a href="https://www.linkedin.com/search/results/all/?keywords=%23pharma&amp;origin=HASH_TAG_FROM_FEED">#Pharma</a></p>



<p class="wp-block-paragraph"></p>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td class="has-text-align-center" data-align="center" colspan="2"><a href="https://en.wikipedia.org/wiki/File:Asundexian.svg"><img loading="lazy" src="https://thumb.wikimedia.org/wikipedia/commons/thumb/3/33/Asundexian.svg/250px-Asundexian.svg.png?utm_source=en.wikipedia.org&amp;utm_campaign=parser&amp;utm_content=thumbnail" height="140" width="250"></a></td></tr><tr><th class="has-text-align-center" data-align="center" colspan="2">Clinical data</th></tr><tr><th class="has-text-align-left" data-align="left"><a href="https://en.wikipedia.org/wiki/Drug_nomenclature#Trade_names">Trade names</a></th><td class="has-text-align-left" data-align="left">Sunharbo</td></tr><tr><th class="has-text-align-left" data-align="left">Other names</th><td class="has-text-align-left" data-align="left">BAY-2433334; BAY2433334</td></tr><tr><th class="has-text-align-center" data-align="center" colspan="2">Legal status</th></tr><tr><th class="has-text-align-left" data-align="left"><a href="https://en.wikipedia.org/wiki/Regulation_of_therapeutic_goods">Legal status</a></th><td class="has-text-align-left" data-align="left"><small><abbr title="United States">US</abbr>:</small> <a href="https://en.wikipedia.org/wiki/Prescription_drug">℞-only</a></td></tr><tr><th class="has-text-align-center" data-align="center" colspan="2">Identifiers</th></tr><tr><td class="has-text-align-center" data-align="center" colspan="2"><a href="https://en.wikipedia.org/wiki/IUPAC_nomenclature_of_chemistry">IUPAC name</a></td></tr><tr><th class="has-text-align-left" data-align="left"><a href="https://en.wikipedia.org/wiki/CAS_Registry_Number">CAS Number</a></th><td class="has-text-align-left" data-align="left"><a href="https://commonchemistry.cas.org/detail?cas_rn=2064121-65-7">2064121-65-7</a></td></tr><tr><th class="has-text-align-left" data-align="left"><a href="https://en.wikipedia.org/wiki/PubChem#CID">PubChem</a> CID</th><td class="has-text-align-left" data-align="left"><a href="https://pubchem.ncbi.nlm.nih.gov/compound/135206011">135206011</a></td></tr><tr><th class="has-text-align-left" data-align="left"><a href="https://en.wikipedia.org/wiki/ChemSpider">ChemSpider</a></th><td class="has-text-align-left" data-align="left"><a href="https://www.chemspider.com/Chemical-Structure.115009501.html">115009501</a></td></tr><tr><th class="has-text-align-left" data-align="left"><a href="https://en.wikipedia.org/wiki/Unique_Ingredient_Identifier">UNII</a></th><td class="has-text-align-left" data-align="left"><a href="https://precision.fda.gov/uniisearch/srs/unii/LA585UM8DE">LA585UM8DE</a></td></tr><tr><th class="has-text-align-left" data-align="left"><a href="https://en.wikipedia.org/wiki/KEGG">KEGG</a></th><td class="has-text-align-left" data-align="left"><a href="https://www.kegg.jp/entry/D12838">D12838</a></td></tr><tr><th class="has-text-align-center" data-align="center" colspan="2">Chemical and physical data</th></tr><tr><th class="has-text-align-left" data-align="left"><a href="https://en.wikipedia.org/wiki/Chemical_formula">Formula</a></th><td class="has-text-align-left" data-align="left">C<sub>26</sub>H<sub>21</sub>ClF<sub>4</sub>N<sub>6</sub>O<sub>4</sub></td></tr><tr><th class="has-text-align-left" data-align="left"><a href="https://en.wikipedia.org/wiki/Molar_mass">Molar mass</a></th><td class="has-text-align-left" data-align="left">592.94&nbsp;g·mol<sup>−1</sup></td></tr><tr><th class="has-text-align-left" data-align="left">3D model (<a href="https://en.wikipedia.org/wiki/JSmol">JSmol</a>)</th><td class="has-text-align-left" data-align="left"><a href="https://chemapps.stolaf.edu/jmol/jmol.php?model=CC%5BC%40%40H%5D%28C%28%3DO%29NC1%3DCC%28%3DC%28C%3DC1%29C%28%3DO%29N%29F%29N2C%3DC%28C%28%3DCC2%3DO%29C3%3DC%28C%3DCC%28%3DC3%29Cl%29N4C%3DC%28N%3DN4%29C%28F%29%28F%29F%29OC">Interactive image</a></td></tr><tr><td class="has-text-align-center" data-align="center" colspan="2"><a href="https://en.wikipedia.org/wiki/Simplified_molecular-input_line-entry_system">SMILES</a></td></tr><tr><td class="has-text-align-center" data-align="center" colspan="2"><a href="https://en.wikipedia.org/wiki/International_Chemical_Identifier">InChI</a></td></tr></tbody></table></figure>



<p class="wp-block-paragraph">//////////Asundexian, anax labs,, APPROVALS 2026, FDA 2026, Sunharbo, LA585UM8DE, <a href="https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22BAY2433334%22[CompleteSynonym]%20AND%20135206011[StandardizedCID]" target="_blank" rel="noopener">BAY2433334</a>, <a href="https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22BAY2433334%22[CompleteSynonym]%20AND%20135206011[StandardizedCID]" target="_blank" rel="noopener">BAY 2433334</a></p>



<figure class="wp-block-image is-resized"><a href="https://newdrugapprovals.org/wp-content/uploads/2023/01/cons-open-a-m-crasto.jpg"><img loading="lazy" width="1024" height="564" data-attachment-id="26263" data-permalink="https://newdrugapprovals.org/2023/01/22/myself-anthony-crasto-up-for-grabs-as-advisor-api-int-chem/cons-open-a-m-crasto/" data-orig-file="https://newdrugapprovals.org/wp-content/uploads/2023/01/cons-open-a-m-crasto.jpg" data-orig-size="1221,673" data-comments-opened="1" data-image-title="cons-open-a-m-crasto" data-image-description="" data-image-caption="" data-large-file="https://newdrugapprovals.org/wp-content/uploads/2023/01/cons-open-a-m-crasto.jpg?w=500" src="https://newdrugapprovals.org/wp-content/uploads/2023/01/cons-open-a-m-crasto.jpg?w=1024" alt="" class="wp-image-26263" style="aspect-ratio:1.8156028368794326;width:1024px;height:auto" srcset="https://newdrugapprovals.org/wp-content/uploads/2023/01/cons-open-a-m-crasto.jpg?w=1024 1024w, https://newdrugapprovals.org/wp-content/uploads/2023/01/cons-open-a-m-crasto.jpg?w=150 150w, https://newdrugapprovals.org/wp-content/uploads/2023/01/cons-open-a-m-crasto.jpg?w=300 300w, https://newdrugapprovals.org/wp-content/uploads/2023/01/cons-open-a-m-crasto.jpg?w=768 768w, https://newdrugapprovals.org/wp-content/uploads/2023/01/cons-open-a-m-crasto.jpg 1221w" sizes="auto, (max-width: 1024px) 100vw, 1024px" /></a></figure>



<figure class="wp-block-image"><a href="http://drugapprovalsint.com/wp-content/uploads/2021/12/str1-17.jpg"><img src="https://i0.wp.com/drugapprovalsint.com/wp-content/uploads/2021/12/str1-17-300x160.jpg" alt="str1" class="wp-image-15152" /></a></figure>



<figure class="wp-block-image"><a href="http://drugapprovalsint.com/wp-content/uploads/2025/10/image-152.png"><img src="https://i0.wp.com/drugapprovalsint.com/wp-content/uploads/2025/10/image-152.png" alt="" class="wp-image-28560" /></a></figure>



<h3 class="wp-block-heading"><strong>AS ON OCT2025 4.511 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT</strong></h3>



<figure class="wp-block-image" id="block-97f20ca3-89bf-4f06-8d2e-7bfa14bb5a13"><img src="https://newdrugapprovals.org/wp-content/uploads/2021/09/wdt-16.jpg" alt="wdt-16" /></figure>



<p class="wp-block-paragraph">join me on Linkedin</p>



<h3 class="wp-block-heading"><a href="https://www.google.co.in/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=1&amp;cad=rja&amp;sqi=2&amp;ved=0CDAQFjAA&amp;url=http%3A%2F%2Fin.linkedin.com%2Fin%2Famcrasto&amp;ei=HC79UIPrOImQrgfThIHgCA&amp;usg=AFQjCNG33yHjtsBnClvr_2VJAspNSOCHjA&amp;sig2=S2Nt_xtNQcl_MGwq9T_I-Q&amp;bvm=bv.41248874,d.bmk"><em>Anthony Melvin Crasto</em> Ph.D – India | <em>LinkedIn</em></a></h3>



<p class="wp-block-paragraph">join me on Researchgate</p>



<h3 class="wp-block-heading"><a href="https://www.researchgate.net/profile/Anthony_Crasto">RESEARCHGATE</a></h3>



<figure class="wp-block-image" id="block-a1fe75ef-39d0-4b9f-a8db-f2ebbfd11320"><img src="https://newdrugapprovals.org/wp-content/uploads/2018/03/research.jpg?w=142" alt="This image has an empty alt attribute; its file name is research.jpg" /></figure>



<p class="wp-block-paragraph">join me on Facebook</p>



<h3 class="wp-block-heading"><em>Anthony Melvin Crasto</em> Dr. | <em>Facebook</em></h3>



<ul id="block-cc73c381-0233-4cde-8597-91f3069d5326" class="wp-block-list">
<li><a href="https://twitter.com/amcrasto">Twitter</a></li>



<li><a href="http://www.facebook.com/anthonymelvin.crasto">FACEBOOK</a></li>
</ul>



<p class="wp-block-paragraph">join me on twitter</p>



<p class="wp-block-paragraph"><em>Anthony Melvin Crasto</em> Dr. | <em>twitter</em></p>



<p class="wp-block-paragraph">+919321316780 call whatsaapp</p>



<p class="wp-block-paragraph">EMAIL. amcrasto@gmail.com</p>



<figure class="wp-block-image is-resized"><a href="https://newdrugapprovals.org/wp-content/uploads/2025/07/image-2.png"><img loading="lazy" width="493" height="277" data-attachment-id="27244" data-permalink="https://newdrugapprovals.org/2025/07/16/keverprazan/image-40/" data-orig-file="https://newdrugapprovals.org/wp-content/uploads/2025/07/image-2.png" data-orig-size="493,277" data-comments-opened="1" data-image-title="image" data-image-description="" data-image-caption="" data-large-file="https://newdrugapprovals.org/wp-content/uploads/2025/07/image-2.png?w=493" src="https://newdrugapprovals.org/wp-content/uploads/2025/07/image-2.png?w=493" alt="" class="wp-image-27244" style="aspect-ratio:1.779783393501805;width:493px;height:auto" srcset="https://newdrugapprovals.org/wp-content/uploads/2025/07/image-2.png 493w, https://newdrugapprovals.org/wp-content/uploads/2025/07/image-2.png?w=150 150w, https://newdrugapprovals.org/wp-content/uploads/2025/07/image-2.png?w=300 300w" sizes="auto, (max-width: 493px) 100vw, 493px" /></a></figure>



<p class="wp-block-paragraph">……</p>
]]></content:encoded>
					
					<wfw:commentRss>https://newdrugapprovals.org/2026/11/12/asundexian/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">34255</post-id>
		<media:content url="https://2.gravatar.com/avatar/569350c7858a75cbcaa674b4e28141525334a91c696621375b3bfee581907c13?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">amcrasto</media:title>
		</media:content>

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-5.jpg?w=1024" medium="image" />

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1.jpg?w=407" medium="image" />

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-1.jpg?w=382" medium="image" />

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-4.jpg?w=1024" medium="image" />

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-3.jpg?w=1024" medium="image" />

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2026/11/s1-2.jpg?w=1024" medium="image" />

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2026/11/image-11ac343d.png?w=618" medium="image" />

		<media:content url="https://thumb.wikimedia.org/wikipedia/commons/thumb/3/33/Asundexian.svg/250px-Asundexian.svg.png?utm_source=en.wikipedia.org&#038;utm_campaign=parser&#038;utm_content=thumbnail" medium="image" />

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2023/01/cons-open-a-m-crasto.jpg?w=1024" medium="image" />

		<media:content url="https://i0.wp.com/drugapprovalsint.com/wp-content/uploads/2021/12/str1-17-300x160.jpg" medium="image">
			<media:title type="html">str1</media:title>
		</media:content>

		<media:content url="https://i0.wp.com/drugapprovalsint.com/wp-content/uploads/2025/10/image-152.png" medium="image" />

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2021/09/wdt-16.jpg" medium="image">
			<media:title type="html">wdt-16</media:title>
		</media:content>

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2018/03/research.jpg?w=142" medium="image">
			<media:title type="html">This image has an empty alt attribute; its file name is research.jpg</media:title>
		</media:content>

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2025/07/image-2.png?w=493" medium="image" />
	</item>
		<item>
		<title>Zemprocitinib</title>
		<link>https://newdrugapprovals.org/2026/11/05/zemprocitinib-2/</link>
					<comments>https://newdrugapprovals.org/2026/11/05/zemprocitinib-2/#respond</comments>
		
		<dc:creator><![CDATA[DR ANTHONY MELVIN CRASTO Ph.D]]></dc:creator>
		<pubDate>Thu, 05 Nov 2026 02:48:05 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[Zemprocitinib]]></category>
		<guid isPermaLink="false">http://newdrugapprovals.org/?p=34251</guid>

					<description><![CDATA[]]></description>
										<content:encoded><![CDATA[
<figure class="wp-block-embed is-type-wp-embed is-provider-new-drug-approvals wp-block-embed-new-drug-approvals"><div class="wp-block-embed__wrapper">
<blockquote class="wp-embedded-content" data-secret="zqVhHHlU9S"><a href="https://newdrugapprovals.org/2025/12/20/zemprocitinib/">Zemprocitinib</a></blockquote><iframe loading="lazy" class="wp-embedded-content" sandbox="allow-scripts" security="restricted"  title="&#8220;Zemprocitinib&#8221; &#8212; New Drug Approvals" src="https://newdrugapprovals.org/2025/12/20/zemprocitinib/embed/#?secret=DRuEs50B3w#?secret=zqVhHHlU9S" data-secret="zqVhHHlU9S" width="500" height="282" frameborder="0" marginwidth="0" marginheight="0" scrolling="no"></iframe>
</div></figure>



<figure class="wp-block-image size-large"><a href="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-4.jpg"><img loading="lazy" width="731" height="332" data-attachment-id="34252" data-permalink="https://newdrugapprovals.org/2026/11/05/zemprocitinib-2/str1-572/" data-orig-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-4.jpg" data-orig-size="731,332" data-comments-opened="1" data-image-title="STR1" data-image-description="" data-image-caption="" data-large-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-4.jpg?w=500" src="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-4.jpg?w=731" alt="" class="wp-image-34252" srcset="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-4.jpg 731w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-4.jpg?w=150 150w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-4.jpg?w=300 300w" sizes="auto, (max-width: 731px) 100vw, 731px" /></a></figure>
]]></content:encoded>
					
					<wfw:commentRss>https://newdrugapprovals.org/2026/11/05/zemprocitinib-2/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">34251</post-id>
		<media:content url="https://2.gravatar.com/avatar/569350c7858a75cbcaa674b4e28141525334a91c696621375b3bfee581907c13?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">amcrasto</media:title>
		</media:content>

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-4.jpg?w=731" medium="image" />
	</item>
		<item>
		<title>Tigozertinib</title>
		<link>https://newdrugapprovals.org/2026/11/04/tigozertinib-2/</link>
					<comments>https://newdrugapprovals.org/2026/11/04/tigozertinib-2/#respond</comments>
		
		<dc:creator><![CDATA[DR ANTHONY MELVIN CRASTO Ph.D]]></dc:creator>
		<pubDate>Wed, 04 Nov 2026 03:08:59 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<guid isPermaLink="false">http://newdrugapprovals.org/?p=34235</guid>

					<description><![CDATA[]]></description>
										<content:encoded><![CDATA[
<figure class="wp-block-embed is-type-wp-embed is-provider-new-drug-approvals wp-block-embed-new-drug-approvals"><div class="wp-block-embed__wrapper">
<blockquote class="wp-embedded-content" data-secret="esD9UeRehv"><a href="https://newdrugapprovals.org/2025/12/12/tigozertinib/">Tigozertinib</a></blockquote><iframe loading="lazy" class="wp-embedded-content" sandbox="allow-scripts" security="restricted"  title="&#8220;Tigozertinib&#8221; &#8212; New Drug Approvals" src="https://newdrugapprovals.org/2025/12/12/tigozertinib/embed/#?secret=GGA3LDO3GI#?secret=esD9UeRehv" data-secret="esD9UeRehv" width="500" height="282" frameborder="0" marginwidth="0" marginheight="0" scrolling="no"></iframe>
</div></figure>



<figure class="wp-block-image size-large"><a href="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-3.jpg"><img loading="lazy" width="472" height="315" data-attachment-id="34236" data-permalink="https://newdrugapprovals.org/2026/11/04/tigozertinib-2/str1-570/" data-orig-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-3.jpg" data-orig-size="472,315" data-comments-opened="1" data-image-title="STR1" data-image-description="" data-image-caption="" data-large-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-3.jpg?w=472" src="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-3.jpg?w=472" alt="" class="wp-image-34236" srcset="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-3.jpg 472w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-3.jpg?w=150 150w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-3.jpg?w=300 300w" sizes="auto, (max-width: 472px) 100vw, 472px" /></a></figure>



<figure class="wp-block-image size-large"><a href="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-1.jpg"><img loading="lazy" width="822" height="895" data-attachment-id="34237" data-permalink="https://newdrugapprovals.org/2026/11/04/tigozertinib-2/str2-80/" data-orig-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-1.jpg" data-orig-size="822,895" data-comments-opened="1" data-image-title="STR2" data-image-description="" data-image-caption="" data-large-file="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-1.jpg?w=500" src="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-1.jpg?w=822" alt="" class="wp-image-34237" srcset="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-1.jpg 822w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-1.jpg?w=138 138w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-1.jpg?w=276 276w, https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-1.jpg?w=768 768w" sizes="auto, (max-width: 822px) 100vw, 822px" /></a></figure>
]]></content:encoded>
					
					<wfw:commentRss>https://newdrugapprovals.org/2026/11/04/tigozertinib-2/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">34235</post-id>
		<media:content url="https://2.gravatar.com/avatar/569350c7858a75cbcaa674b4e28141525334a91c696621375b3bfee581907c13?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">amcrasto</media:title>
		</media:content>

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2026/11/str1-3.jpg?w=472" medium="image" />

		<media:content url="https://newdrugapprovals.org/wp-content/uploads/2026/11/str2-1.jpg?w=822" medium="image" />
	</item>
	</channel>
</rss>
